 
 
Document  type:  Clinical study protocol  
Title: Effects of oral levosimendan (ODM -109) on respi[INVESTIGATOR_654123]: [REMOVED] 
Document date:  26 March 2020  
 
ODM -109
Clinical study protocol 3119002 – Amendment 3
Sponsor approvals:
 
 
 
DNO 090017ff823c9bac  /  . 2 / 58 DNO 090017ff823c9bac Approved  /  1.0 2 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877639] ................................ ................................ ................................ ......23
5.3 Dosing ................................ ................................ ................................ ........................ 23
5.3.1 Selection and timing of doses ................................ ................................ ................ 23
5.3.2 Dose adjustment ................................ ................................ ................................ ....23
5.4 Method of assigning study  subjects to treatment groups ................................ ........... 24
5.5 Blinding................................ ................................ ................................ ...................... 24
5.6 Emergency  procedures ................................ ................................ ............................... 24
DNO 090017ff823c9bac  /  . 3 / 58 DNO 090017ff823c9bac Approved  /  1.0 3 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877640] discontinued the study  medication ....... 32
6.2 Efficacy assessments ................................ ................................ ................................ ..32
6.2.1 Slow Vital Capacity ................................ ................................ .............................. 32
6.2.2 Revised AL S Functional Rating Scale ................................ ................................ ..33
6.2.3 Time to respi[INVESTIGATOR_654124] ................................ ................................ ...................... 33
6.2.4 Clinical Global I mpression ................................ ................................ .................... 33
6.2.5 Borg Category  Ratio 10 Scale ................................ ................................ ............... 34
6.2.6 Epworth Sleepi[INVESTIGATOR_7110] ................................ ................................ ...................... 34
6.2.7 Pi[INVESTIGATOR_10797] ................................ ................................ ............. 34
6.2.8 Health care and home care resource use ................................ ............................... 34
6.2.9 Other assessment s ................................ ................................ ................................ .35
6.3 Pharmacokinetic assessments ................................ ................................ .................... 35
6.3.1 Blood sampling ................................ ................................ ................................ .....35
6.3.2 Determination of levosimendan, OR -1855 and OR -1896 concentrations in 
plasma ................................ ................................ ................................ .................... 35
6.3.3 Determination of riluzole concentrations in plasma ................................ ............. 35
6.3.4 Calculation of pharmacokinetic var iables ................................ ............................. 35
6.4 Biomarker, pharmacogenomic and other specific biological variables ..................... 36
6.4.1 Biomarkers ................................ ................................ ................................ ............ 36
6.4.2 Pharmacogenomics ................................ ................................ ................................ 36
6.5 Safety  assessments ................................ ................................ ................................ .....37
6.5.1 Adverse events ................................ ................................ ................................ ......37
[IP_ADDRESS] Definitions ................................ ................................ ................................ ........ 37
DNO 090017ff823c9bac  /  . 4 / 58 DNO 090017ff823c9bac Approved  /  1.0 4 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
[IP_ADDRESS] Assessment of adverse events ................................ ................................ .......... 38
[IP_ADDRESS] Reporting of serious adverse events by  [CONTACT_093] ................................ ..38
[IP_ADDRESS] Reporting of serious adverse events to competent authorities and ethics 
committees ................................ ................................ ................................ ........ 39
6.5.2 Special situations ................................ ................................ ................................ ...40
6.5.3 Pregnancy  during the study ................................ ................................ ................... 40
6.5.4 Clinical safety  assessments ................................ ................................ ................... 40
6.5.5 Assessment of suicidality ................................ ................................ ...................... 41
6.5.6 L aboratory  safet y assessments ................................ ................................ .............. 41
6.6 Changes implemented due to COVID- 19 pandemic ................................ ................. 42
7. D ATA COLLECTION AND M ANAGEMENT ................................ ................................ ........... 44
8. S TATISTICAL METHODS ................................ ................................ ................................ ....45
8.1 Statistical hy potheses ................................ ................................ ................................ .45
8.2 Estimation of sample size ................................ ................................ .......................... 45
8.3 Analy sis populations ................................ ................................ ................................ ..46
8.4 Statistical analy ses................................ ................................ ................................ .....46
8.4.1 Demographic and other baseline characteristics ................................ ................... 46
8.4.2 Treatment compliance and extent of exposure ................................ ...................... 46
8.4.3 Analysis of efficacy ................................ ................................ ............................... 46
8.4.4 Pharmacokinetic anal ysis................................ ................................ ...................... 47
8.4.5 Population PK/PD modelling ................................ ................................ ................ 47
8.4.6 Evaluation of pharmacogenomics ................................ ................................ ......... 47
8.4.7 Evaluation of exploratory  biomarkers................................ ................................ ...48
8.4.8 Safety  anal ysis................................ ................................ ................................ ....... 48
[IP_ADDRESS] Analy sis of adverse events ................................ ................................ ............... 48
[IP_ADDRESS] Clinical safety  anal ysis................................ ................................ ..................... 48
[IP_ADDRESS] Laboratory  safet y anal ysis................................ ................................ ................ 48
[IP_ADDRESS] Analy sis of prior and concomitant treatments ................................ .................. 49
[IP_ADDRESS] Analy sis of suicidality ................................ ................................ ...................... 49
8.5 Interim anal yses................................ ................................ ................................ ......... 49
9. D ATA QUALITY ASSURANC E................................ ................................ ............................. 49
9.1 Training ................................ ................................ ................................ ...................... 49
9.2 Case report forms ................................ ................................ ................................ ....... 49
9.3 Monitoring, audits and inspections................................ ................................ ............ 49
9.4 Laboratories and other vendors ................................ ................................ .................. 50
DNO 090017ff823c9bac  /  . 5 / 58 DNO 090017ff823c9bac Approved  /  1.0 5 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877641] OF TA BLES
Table 1. Schedule of stud y events ................................ ................................ ....................... 27
Table 2. Procedures at visit 1 (baseline) ................................ ................................ .............. 30
Table 3. Procedures at visits 2 -8 ................................ ................................ ......................... 31
Table 4. Procedures during additional visits ................................ ................................ ....... 32
Table 5. Blood sampling for the determination of levosimendan and its metabolites 
concentrations ................................ ................................ ................................ ........ 35
Table 6. Mean (SD) change from baseline SVC (supi[INVESTIGATOR_050])................................ ................... 46
DNO 090017ff823c9bac  /  . 6 / 58 DNO 090017ff823c9bac Approved  /  1.0 6 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
SYNOPS IS
Sponsor: Orion Corporation Orion Pharma
Finished product: Not applicable
Active pharm aceutical ingredient: Oral levosime ndan ( ODM -109)
Study title: Effects of oral levosimendan ( ODM -109)on respi[INVESTIGATOR_654125]: 3119002
Investigator: The s tudy coordinating investigator [INVESTIGATOR_654126].
Study centres : This will be a multinational study in approximately 100 centres.
Developm ent phase: III
Objectives: The primary objective of this study is to confirm that levosimendan can significantly improve 
respi[INVESTIGATOR_654127] ( SVC )in amyotrophic lateral sclerosis ( ALS )patients.
The secondary objective is to confirm that levosimendan improves the functionality of subjects, measured by 
[CONTACT_654201] (ALSFRS -R), Clinical Global Impression (CGI ),Borg Category Ratio 10 
(CR10) scale on dyspnoea ,Epworth Sleepi[INVESTIGATOR_50526] (ESS) and Pi[INVESTIGATOR_2272] (PSQI). The latter 
two are sleep scales assessing daytime somnolence and sleep quality, respectively. In addition, the long-term 
tolerability and safety of levosimendan in ALS patients will be evaluated, asses sing up to 48 w eeks of exposure . 
Other objec tives: For the purposes of potential later pharm acoeconomic analysis, the use of specific health and home 
care resources and assistive devices will be quantified. This will include both in and outpatient care, as well as formal 
and informal home care.
Exploratory objectives: The plasm a concentrations of levosimendan and the metabolites OR-1855 and OR-1896 will 
be determined . In addition, a population pharmacokinetic/pharmacodynamic (PK/PD) model between OR -1855 and 
OR-1896 exposure and efficacy related endpoints and heart rate (HR)will be explored. Plasma concentrations of 
riluzole will also be determined. The effects of levosimendan, OR-1855 and OR-1896 on plasma trough 
concentrations of riluzole will be evaluated. The acetylation status will be determined for all subjects to assess 
whether it affects the PDresponses of levosimendan in patients with ALS.
Methodology: This is a randomised, double- blind, placebo -controlled, parallel -group, multinational, multicentre 
study .The subjects will be allocated to 2 parallel groups receiving either levosimendan 1 -2 mg d aily or placebo in  
2:1ratio.There w ill be a screening visit, a baseline visit follow ed by  [CONTACT_499360] 2, 4, 8, 12, 24, [ADDRESS_877642] will be about 51-52 weeks 
including the end-of-study visit.
Number of subjects: The planned number of subjects is approximately 450.
Diagnosis and main criteria for inclusion: Male or female subjects with diagnosis of ALS, disease duration from 
symptom onset of 12- 48 months, written or verbal informed consent (IC) obtained from the subject. Age at least 18 
years. Able to swallow study treatment capsules, and in the opi[INVESTIGATOR_871], is expected to continue to do 
so during the study. Sitting SVC between 60-90% of the predicted value for age, height and sex at screening visit. 
Able to perform supi[INVESTIGATOR_654128]. Subjects with or without riluzole and/or edaravone. If 
using riluzole (any daily dose up to 100 mg), the dose must have been stable for at least [ADDRESS_877643] 
4 weeks before the screening visit (at least one 28-day treatm ent cycle as indicated) and should not be changed 
during the study .If not on riluzole and/or edaravone , therespective treatments should notbestartedduring the study.
Investigational medicinal product, dose and m ode of administration: Levosim endan [ADDRESS_877644], dose and m ode of administration: Placebo Levosimendan caps ule
Frequency/ duration of treatm ent: The daily doses of oral levosimendan will be 1-2 mg depending on the 
tolerability (mainly judged by [CONTACT_84888]). The subjects will start with a 1mg dose (in the morning) for 2weeks.
Administration of placebo (1 or 2 capsules per day) w ill be based on the same cr iteria asfor levosimendan.
Bioanalytical methods: The concentrations of levosimendan, OR-1855, OR-1896 and riluzo le in plasma will be 
determined by [CONTACT_597506] –tandem mass spectrometry (LC -MS/MS) methods.
DNO 090017ff823c9bac  /  . 7 / 58 DNO 090017ff823c9bac Approved  /  1.0 7 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
Variables and methods of ass essments:
Efficacy:
The primary efficacy variable will be the change from baseline at12 weeks in SVC measured in supi[INVESTIGATOR_2547], 
SVC (supi[INVESTIGATOR_050]). All SVC measurements prior to 12 weeks will be included in the statistical model.SVC is the 
maximum volume of air that can be exhaled slowly after slow maximum inhalation.
ALSFRS -Rwill be assesse d. The variables derived w ill be the scores of the 12 separate item s, the total scores 
of each subdomain and the total score of ALSFRS -R. 
The ‘Time to respi[INVESTIGATOR_110636]’ composite endpoint will be used to validate the changes seen in supi[INVESTIGATOR_654129] . 
This variable consists of the follow ing events:
-At least 1 point decrease in ALSFRS -R respi[INVESTIGATOR_654130] 10, 11 or 12
-Meeting ‘protocolised’ criteria for NIV: supi[INVESTIGATOR_654129] ≤ 50% predicted
-Starting NIV (actual start or attempt to start NIV)
-Invasive mechanical ventilation by [CONTACT_654202][INVESTIGATOR_654131] w henever any of the [ADDRESS_877645] met.
CGI is used to rate the severity of subjects’ clinical condition. Clinical condition is assessed by [CONTACT_654203] a visual analogue scale (VAS).
Perception on the intensity of dyspnoea will be assessed by [CONTACT_654204]10 scale insupi[INVESTIGATOR_546807].
Daytime som nolence will be assessed by [CONTACT_654205].
Sleep quality and disturbances w ill be assessed by [CONTACT_654206] .
Health care and home care resource use will be assessed for possible later use in pharmacoeconomic analysis.
Other assessments: Subject’s status for NIV support, invasive mechanical ventilation by [CONTACT_654207].
Pharm acokinetics (PK) : Blood samples for the determination oflevosimendan, its metabolites OR -1855 and OR-
1896 and riluzole concentrations in plasma will be collected .
Biom arkers: Blood sam ples will be collected for exploratory biom arker analyses which may give supportive data 
related to the disease state of the subjects.
Pharm acogenomics (PG): All subjects will provide a blood sample for determination of subject s’acetylation status 
(NAT polymorphisms). The DNA of subjects who have given a separate PG IC will be stored to allow  possible 
exploratory PG research to assess whether genetic polymorphisms relate to the absorption, distribution, metabolism, 
excretion, pharmacodynamics or safety of levosimendan .
Safety: Safety will be assessed by [CONTACT_20721] (AEs), vital signs , 12-lead electrocardiograms (ECGs) ,physical 
examination , weight ,laboratory te stsand by [CONTACT_654208] .
Statistical methods :The primary efficacy variable SVC (supi[INVESTIGATOR_050]) will be compared between the treatment arms 
using the mixed model for repeated measures (MMRM )with between subject effects for treatment, centre and 
randomisation strata, time as within subject effect, and baseline value (visit 1) as a covariate. Primary efficacy will 
be evaluated at [ADDRESS_877646] of 
missing data imputation will be evaluated analysing observed data only and estimating the slope of decline using 
the random slope model. Several sensitivity subgroup analyses will be performed and defined in the statistical 
analysis plan ( SAP). Additional evaluations will be performed including all data through 48 w eeks, using MMRM.
Secondary efficacy endpoints will be tested in following hierarchy to preserve the overall alpha l evel:
1. Com bined assessment of ALSFRS -Rfunction and survival through 48 w eeks
2. Time to respi[INVESTIGATOR_654132] 48 w eeks
3. CGI through 48 w eeks
4. Supi[INVESTIGATOR_654133] 10 scale at 12weeks
5. Slope of decline in respi[INVESTIGATOR_654134] -R through 48weeks
The efficacy variables time to respi[INVESTIGATOR_110636], time to NIV or death, time to SVC (supi[INVESTIGATOR_050]) decline of 20% , time to 
SVC (supi[INVESTIGATOR_050]) ≤50% of predicted , time to ALSFRS -R total score decline of 20 % and time to decline in ALSFRS -R 
respi[INVESTIGATOR_654135]’s proportional regression model. The model will include effect for 
treatment and will be adjusted for randomisation strata. Prem ature discontinuations will be censored from the 
analyses. Censoring rules will be defined in the SAP.
DNO 090017ff823c9bac  /  . 8 / 58 DNO 090017ff823c9bac Approved  /  1.0 8 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877647] e imputation method will be considered.
CGI, Borg CR10 (sitting , supi[INVESTIGATOR_654136]) , ESS and PSQI will be evaluated using the MMRM and 
estimates for individual time points will be done using contrasts. In addition categorical analyses for ESS and PSQI 
will be performed using repeated measures logistic regression using the generalised estimating equation (GEE) 
approach.
All efficacy data w ill be listed and summarised over the time and by [CONTACT_654209].
Standard safety evaluations will be performed for AEs, vital signs, 12-lead ECG ,safety laboratory variables and 
suicidality .
DNO 090017ff823c9bac  /  . 9 / 58 DNO 090017ff823c9bac Approved  /  1.0 9 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877648] Aspartate aminotransferase
ATP Adenosine triphosphate
AV Atrioventricular
b.i.d. Twice a day
BMI Body mass index
BP Blood pressure
bpm Beats per minute
CA Competent authority
CAFS Combined assessment of function and survival
CHF Chronic heart failure
CGI(-C) Clinical Global I mpression (of Change)
Cmax Maximum concentration
CMV Cytomegalovirus
CNS Central nervous s ystem
COPD Chronic obstructive pulmonary  disease 
CR10 Category  Ratio [ADDRESS_877649]
EBV Epstein -Barr virus 
EC Ethics committee
ECG Electrocardiogram
DNO 090017ff823c9bac  /  . 10 / 58 DNO 090017ff823c9bac Approved  /  1.0 10 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877650]
ITT Intent -to-treat
i.v. Intravenous
IWRS Interactive web response sy stem
LC-MS/MS Liquid -chromatograph y-tandem mass spectrometry
MedDRA Medical Dictionary  for Regulatory  Activities
DNO 090017ff823c9bac  /  . 11 / 58 DNO 090017ff823c9bac Approved  /  1.0 11 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
MG Myasthenia gravis
MHRA The Medicines and Healthcare Products Regulatory  Agency
MMRM Mixed model for repeated measures
NIV Non-invasive mask ventilation
PD Pharmacod ynamic(s)
PG Pharmacogenomic(s)
PK Pharmacokinetic(s)
PP Per-protocol
QTcF QTc Fridericia
SAE Serious adverse event
SAP Statistical analy sis plan
SBP Systolic blood pressure
SNP Sniff nasal pressure
SVC Slow vital capacit y
t1/[ADDRESS_877651] Upper limit of normal
Note on usage of terms:
Orion Corporation Orion Pharma is hereafter in this document called “Orion” or sponsor .
The term ‘investigator ’in the text of the protocol refers to the principal investigator [INVESTIGATOR_5768]-
investigator. 
DNO 090017ff823c9bac  /  . 12 / 58 DNO 090017ff823c9bac Approved  /  1.0 12 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
1.INTRODUCTION
1.1 Background
Amy otrophic lateral sclerosis (ALS) is a rare, rapi[INVESTIGATOR_654137]. The latter is due to the weakness and loss 
of diaphragm m uscle strength. The median survival time from s ymptom onset is approximately 
3 years (Turner MR et al., 2013 ). There is an unmet need for new treatments in AL S. The reare 
3drugscurrentl y indicated for ALS . The first was riluzole, which has only modest effects 
(approx. 3 months) on the survival of ALS patients (Bensi mon G et al., 1994 )and no
symptomatic effects . Riluzole is globally  available. In addition, two new drugs have recently  
been approved for ALS in the US. Edaravone has modest effects on the Revised ALS Functional 
Rating Scale (ALSFRS -R), but does not specifically  address muscle weakness and respi[INVESTIGATOR_654138]. The other one isdextromethorphan/quinidine indicated for the 
symptomatic treatment of pseudobulbar affect . In later stage patients with significantly 
compromised respi[INVESTIGATOR_60324] , it is a common practice to initiate non-invasive mask 
ventilation (NIV) to improve patients’ qualit y of life and survival (Andersen PM et al., 2012 , 
NICE guideline [NG42], 2016 ).
Almost all of the new molecules under development are disease modifying in nature (Zinman L 
et al., 2011 ). Exception sare fast skeletal muscle troponin activator s,tirasemtiv and reldesemtiv
(CK-2127107 ), which increas ethe efficiency  of muscle contraction. Despi[INVESTIGATOR_654139] (slow vital capacity  [SVC]) in a 3 -month phase II  study  in patients with 
ALS (Shefner JM et al., 2016 )tirasemtiv did not show benefits over placebo in any of the 
primary  or secondary  endpoints in a recentl y completed phase III study (Press release, 2017) . A 
phase II study investigating the effects of reldesemtiv on measures of respi[INVESTIGATOR_654140] s with AL Sis currentl y ongoing .
Levosimendan is an inodilator originally  developed for the treatment of heart failure (HF). The 
clinical intravenous (i.v.) programme included about [ADDRESS_877652] 2000 
patients received levosimendan. Currentl y i.v. formulation of levosimendan (Simdax®) is 
registered in 60countries . In these patients, levosimendan significantly increases cardiac output 
thus providing inotropic support to overcome the acute w orsening of HF. The m ain mechanism 
of action of levosimendan is a selective binding to troponin C (Haikala H et al., 1995) and 
subsequent sensitisation of cardiac and fast and slow skeletal muscles to calcium. In addition, 
levosimendan opens ATP -sensitive potassium channels on the sarcolemma of smooth muscle 
cells and in the mitochondria of cardiomy ocytes and has vasodilatory effects via potassium 
channel opening and antiaggregatory  effects on thrombocy tes. Levosimendan does not increase 
consumption of ATP or oxygen (Deschodt -Arsac V et al., 2010) and does not have any direct 
central nervous system (CNS) effects in laboratory  animals with plasma concentrations up to 
> 10-100 times higher than those seen with dail y oral levosimendan doses of 1 -2 mg in man.
Levosimendan is metabolised by [CONTACT_654210]-1855, which is further acetylated to 
OR-1896. About 5% of the levosimendan dose is converted to OR-1896. Both metabolites are 
active, but OR-[ADDRESS_877653] affects the formation of the active metabolites so that rapid 
acetylators produce mo re OR -1896 than slow acety lators. Howev er, the haemody namic effects 
DNO 090017ff823c9bac  /  . 13 / 58 DNO 090017ff823c9bac Approved  /  1.0 13 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877654] of the parent drug and its metabolites; the main effect thought to be 
derived mainl y from the long -acting metabolite OR -1896. 
After oral administration in healthy  subjects, the maximum concentration (Cmax) of 
levosimendan (mean approx. 45 ng/ml) in plasma was seen at 1 hour after doses of 1 mg once a 
day or 1 mg twice a day (b.i.d.). However, the active metabolite (OR-1896) concentrations 
increase slowly  and steady -state is achieved after 12-14 days with constant daily  dosing. The 
mean Cmaxof OR-1896 after 14 days of dosing with daily  levosimendan doses of 1 and 2 mg 
were 1.6 and 2.8 ng/ml, respectivel y. The elimination half -life (t1/2) of levosimendan is about [ADDRESS_877655] phase IIastudy  in ALS (LEVAL S, 3119001), oral levosimendan has been studied 
in healthy subjects, in patients with HF and in a small number of patients with a recent history 
of ischemic stroke/transient ischemic attack (TIA). 
In the 2 earlier dose -ranging studies in 90 patients with HF, 5 doses of oral levosimendan from 
0.25 to 4 mg or placebo were administered 4 times daily  for 2 -4 weeks. Daily  doses of 4 -16 mg 
had beneficial haemod ynamic effects, but daily  doses of 8-16 mg were associated with increased 
(> 10 beats per minute [bpm]) heart rate (HR). Despi[INVESTIGATOR_654141]-1896 (1.3 to 28.5 ng/ml in the different dose groups), no signs of acute 
tolerability  problems were seen. 
The largest study  with oral levosimendan, the PERSI ST study  (Nieminen MS et al., 2008 ), was 
a placebo -controlled study  in 307 patients with sever echronic heart failure (CHF). The studied 
levosimendan doses were [ADDRESS_877656] 180 days. The results were inconclusive; quality of life (QoL) improved and the number of 
worsening HF events decreased, but mortality  was numericall y higher in levosimendan treated 
patients. The low overall mortality  and the fact that the highest number of deaths was seen in the 
levosimendan [ADDRESS_877657] played an important role in distribution of deaths. HR increased by [CONTACT_3450]  8bpm 
compared to placebo in both levosimendan groups. In this study , HR increase and palpi[INVESTIGATOR_654142] (AEs) reported statistically  more frequentl y with levosimendan 
compared to placebo. The number sof atrial fibrillations or ventricular arrhy thmias reported were
similar between patients receiving levosimendan and placebo.
In a small study  (5 and 16 patients randomised to placebo and levosimendan, respectivel y) 
conducted in TIA/stroke patients with increasing doses of oral levosimendan (from 0.125 mg up 
to 2 mg daily), all doses increased cerebral blood flow velocit y (Kivikko M et al., 2015 ). Systolic 
and/or diastolic blood pressure (BP) decreased by [CONTACT_101432]. 5-7 mmHg with daily  levosimendan 
doses of 1-2 mg. In turn, HR increased by  [CONTACT_101432]. 6 -8 bpm with daily  doses of 0.5 -2 mg. Only 
the 2 mg daily  dose increased the number of ventricul ar extrasystoles per hour above a 
predefined limit (set to reflect thepossible increased risk of proarrhy thmic effects in 
cardiovascular patients) compared to baseline. There were no significant differences in 
arrhythmias or adverse events ( AEs)reported between placebo and levosimendan. 
Levosimendan has been shown to improve the force generation of diaphragm muscle fibres 
obtained from a rat model of HF (van Hees HW et al., 2011 ). The same has been reported with 
diaphragm muscle fibr es obtained from lung cancer patients during surgery  (van Hees HW et 
al., 2009 ). Both of these studies reported that the beneficial force generating effects of 
DNO 090017ff823c9bac  /  . 14 / 58 DNO 090017ff823c9bac Approved  /  1.0 14 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877658] muscle fibr es. In addition, the same group 
demonstrated that levosimendan (i.v.) improved the neuromechanical efficiency  and 
contractility  of human diaphragm function in healthy  subjects (Doorduin J et al., 2012 ). In an 
antibody -induced my asthenia gravis (MG) rat model, levosimendan (0.25 mg/kg orall y) and its 
long-acting metabolite OR-1896 (0.025 mg/kg) given as a single dose significantly  improved 
motor performance in the accelerating RotaRod test as well as exercise capacity  in the Treadmill 
test. These beneficial effects are thought to be due to improved skeletal muscle strength and 
endurance (Orion Report).
LEVAL S (3119001) was a randomised, double -blind, placebo- controlled, crossover, 3-period, 
multicentre phase IIa study  in 66 ALS patients with a 6-month open -label part. Randomised 
treatments for the cross over part were placebo and levosimendan with 1 mg and 2 mg daily 
doses. Each treatment period during the double -blind, placebo- controlled part lasted for 14 (± 2) 
days separated by  a 19 -23 day s wash -out period. 
In the primary  efficacy  variable, SVC% (sitting) there was a clear period effect in the data. 
Therefore ,period-w ise baselines were justified and used in efficacy  analyses (post -hoc). The 
estimated mean changes from baseline were -0.67, -0.98 and -0.01% points for placebo, 
levosimendan 1 mg daily  (p = 0.97 vs. placebo) and levosimendan 2 mg daily  (p = 0.85 vs. 
placebo), respectively .
Secondary  and other efficacy  variables were analy sed using period- wise baselines (post -hoc 
analysis). In the secondary  efficacy  variable SVC% (supi[INVESTIGATOR_050]), the estimated mean differences 
from baseline were - 3.62, +0.77 and +2.38 % poi nts for placebo, levosimendan 1 mg daily (p = 
0.018 vs. placebo) and levosimendan 2 mg daily  (p = 0.001 vs. placebo), respectively . In other 
words, both levosimendan doses (in a dose-dependent manner) improved SVC% (supi[INVESTIGATOR_050]) values 
during the 2-week treatment period, whereas SVC% (supi[INVESTIGATOR_050]) decreased during placebo. The 
treatment effects between placebo and levosimendan 1 mg and 2 mg were 4.39% and 6.00%, 
respectivel y, favouring levosimendan. Both levosimendan doses were numericall y better 
compared to placebo inthe ALSFRS -R total score. The estimated mean differences from 
baseline were -0.82, - 0.46 and -0.37 for placebo, levosimendan 1 mg daily  (p = 0.49 vs. placebo) 
and levosimendan 2 mg daily (p = 0.34 vs. placebo), respectivel y. For the ALSFRS -R respi[INVESTIGATOR_654143] -0.22, +0.04 and +0.05 for placebo, 
levosimendan 1 mg daily  (p = 0.13 vs. placebo) and levosimendan 2 mg daily  (p = 0.12 vs. 
placebo), respectively . These small numerical trends seen in the ALSFRS -R total andrespi[INVESTIGATOR_654144] s provide support for supi[INVESTIGATOR_654145]. 
There were no statistically  significant differences seen between placebo and levosimendan 1mg 
and 2 mg daily treatments in sniff nasal pressure (SNP), visual analogue scale (VAS) of fatigue, 
overnight oxygen saturation (SpO 2) measured by a pulse oximeter, maximal hand grip strength 
and submaximal hand grip endurance or Clinical Global Impression of Change (CGI -C) assessed 
by [CONTACT_27379] . 
Tolerability  and safety were good in general in the LEVA LS study  and similar to previous 
studies with oral levosimendan. As expected, AEs of headache and increased HR were more 
common during levosimendan (in a dose-dependent manner) and the latter led to study  treatment
discontinuations based on a predefined criteri on(increase in HR> 15 bpm compared with 
screening). The number sof severe AEs or serious adverse events (SAEs) were similar between 
levosimendan and placebo. There were no differences either in supraventricular or ventricular 
tachyarrh ythmias between the treatments. 
DNO 090017ff823c9bac  /  . 15 / 58 DNO 090017ff823c9bac Approved  /  1.0 15 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877659] favouring levosimendan in SVC% supi [INVESTIGATOR_81995] 2 week streatment. 
Collectively  these results indicate that levosimendan is able to improve the muscle strength 
endurance of diaphragm and therefore respi[INVESTIGATOR_654146] S.
1.2 Rationale of the study
1.2.1 Rationale of the study  design
The aim of this pi[INVESTIGATOR_654147]% 
results seen in the LE VALS phase II astudy  and to demonstrate benefit on supporting endpoints
such as ALSFRS -R and the composite of ‘time to’ respi[INVESTIGATOR_50127] .
The target population is subjects with diagnosis of laboratory  supported probable, probable or 
definite ALS according to the El Escorial revised criteria (Brooks BR et al., 2000 ). The main 
inclusion criterion will be SVC% (sitting)between 60-90% of predicted . It is believed that 
enrolling patients who alread y have some respi[INVESTIGATOR_654148] . This might be the case particularly on respi[INVESTIGATOR_120340], which are not present early in the disease . The SVC % (supi[INVESTIGATOR_050] )results in the 
LEVAL S study  support using this SVC% range also in this phase III study.
SVC% assessed in the supi[INVESTIGATOR_654149]. In the LEVALS 
study , both levosimend an doses were superior to placebo in supi[INVESTIGATOR_654129]%. Assessing SVC in 
the supi[INVESTIGATOR_654150], because the first clinical signs of respi[INVESTIGATOR_654151]. There is also evidence that vital 
capacity  measured in the supi[INVESTIGATOR_654152] (Lechtzin N et al., 2002 )and is a better predictor of survival 
compared with upright vital capacity  (Schmidt EP et al., 2006 , Baumann F et al., 2010 ).
There will be 2futility /interim analyses, first when about 50% and second when 100% of 
subjects have been treated for 12 weeks . Based on these analyses, the study  will be stopped in 
case the futility /interim analysis indicates that statistically  significant differences between the 
treatment arms are unlikely  at the planned study  end.
The double -blind treatment duration will be [ADDRESS_877660] controlled long-term 
safet y and efficacy  data. The pri mary  efficacy  variable (SVC% supi[INVESTIGATOR_050]) will be analysed at 12 
weeks. Supporting secondary  variables such as ‘time to’ respi[INVESTIGATOR_654153] -R 
require longer treatment duration to demonstrate benefit and will be examined at 48 weeks.
1.2.2 Rationale for selected doses
The LEVA LS phase II astudy  included treatment periods with 1 mg once a day  and 1 mg b.i.d.
of levosimendan. These two daily  doses of levosimendan showed significant benefits over 
placebo in supi[INVESTIGATOR_654154] a dose -dependent manner. Based on the LEVALS results and studies 
in cardiac and other patient populations, higher doses are associated with increased HR. 
Therefore Orion concludes that no further dose finding is needed. The target maintena nce dose 
DNO 090017ff823c9bac  /  . 16 / 58 DNO 090017ff823c9bac Approved  /  1.0 16 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877661] shown that levosimendan may be associated with head ache in a dose-dependent 
manner, lasting for about 2-3 days. Starting with 1 mg per day will therefore decrease the 
occurrence of headache. HR has also been shown to increase dose-dependently  with 
levosimendan. If tolerability  allows (e.g. based on HR) at 2 weeks , the dose will be increased to 
1 mg b.i.d.If required due to any tolerability  issues (e.g. based on HR) during 1mg b.i.d.dosing, 
the dose can be decreased to [ADDRESS_877662]
goes to bed.
1.3 Benefit-risk assessment
1.3.1 Potential benefits associated with levosimendan
SVC assessed in the supi[INVESTIGATOR_654155] S study  indicated that levosimendan can 
significantl y improve the skeletal muscle function ofthediaphragm, thereb y supporting 
respi[INVESTIGATOR_654156]. This in turn is expected to improve patients’ well-being 
and functional ability .
1.3.[ADDRESS_877663] signs of toxicity appearing at 2-5 fold clinical exposure. The clinical relevance of these 
findings is not known. Based on the safet y data originating from the completed clinical trials 
with oral levosimendan (administered 1-2 mg  daily  for longer than 180 day s), safety  signals of 
increased heart rate and palpi[INVESTIGATOR_654157] n detected and are considered as potential risks for 
oral levosimendan use. No other safety concerns related to cardiac function have been identified
from these data.Arrhy thmias are known AEs for i.v. levosimendan in patients with severe CHF. 
However, there is no such evidence for oral levosimendan in healthy  subjects. In addition, the 
LEVAL S phase IIastudy  conducted in ALS patients did not find any differences in 
supraventricular or ventricular tachy arrhy thmias between placebo and levosimendan. There 
were no differences either in the number sof severe AEs or SAEs between the treatments. 
However, special attention should be paid to symptoms potentially  connected with cardiac 
arrhythmias, such as palpi[INVESTIGATOR_814], dizziness and loss of consciousness. Headache (due to 
vasodilatation), increased HRand palpi[INVESTIGATOR_654158]/or AL S patients treated with levosimendan . In laboratory  
parameters, slight decreases in red cell parameters and serum potassium have been observed in 
some studies.
1.3.3 Potential risks associated with the study  assessments
Blood samples will becollected for safety  laboratory , pharmacokinetic (PK)and 
pharmacogen omic (PG) analyses.The risks of blood sampling include fainting and pain, 
DNO 090017ff823c9bac  /  . 17 / 58 DNO 090017ff823c9bac Approved  /  1.0 17 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
bruising, swelling or rarely  infection of the injection site. Electrocardiogram ( ECG )pads can 
cause skin irritation and the removal of the pads can be painful. Repeated respi[INVESTIGATOR_654159] S.
2.STUDY OBJECTIVES
2.1 Primary  objective
The primary  objective of this study  is to confirm that levosimendan can significantly  improve 
respi[INVESTIGATOR_654160].
2.2 Secondary  objective
The secondary  objective isto confirm that levosimen dan improves the functionality  of subjects
measured by [CONTACT_191953] -R, CGI, Borg Category Ratio 10 (CR10) s cale on the intensity  of 
dyspnoea , Epworth Sleepi[INVESTIGATOR_50526] (ESS)and Pi[INVESTIGATOR_10797] (PSQI ). The latter 
two are sleep scales assessing daytime somnolence and sleep quality , respectively . In addition ,
the long-term tolerability  and safet y of levosimendan in ALS patients will be evaluated, 
assessing up to 48 weeks of exposure.
2.3 Other objectives
For the purposes of potential later pharmacoeconomi c analy sis, the use of specific health care 
resource s will be quantified on weekl y basis , including:
The number of day sspent in hospi[INVESTIGATOR_10422] .
The number of additional visits to a hospi[INVESTIGATOR_654161].
The average number of formal home care hours per day on the given week (paid/public 
services obtained) and the number of times such care was received during a usual night .
The average number ofinformal home care hours per day on the given week (unpaid; by 
[CONTACT_5569] , other relative, friend or volunteer) and the number of times such care was 
received during a usual night . 
The number of days spent in institutional care other than hospi[INVESTIGATOR_307] (e.g. 
respi[INVESTIGATOR_040]/ hospi[INVESTIGATOR_6125]/ nursing home/rehabilitative care ).
Receipt of new, non-medicinal assistive devices and other aids .
2.4 Exploratory  objectives
The p lasma concentrations of levosimendan and the metabolites OR- 1855 and OR -1896 will be 
determined. In addition, a population pharmacokinetic/pharmacod ynamic (PK/PD) model 
between OR-1855 and OR-1896 exposure and efficacy  related endpoints and HR will be 
explored. Plasma concentrations of riluzole will also be determined. The effects of 
levosimendan, OR-1855 and OR-1896 on plasma trough concentrations of riluzole will be 
evaluated.
DNO 090017ff823c9bac  /  . 18 / 58 DNO 090017ff823c9bac Approved  /  1.0 18 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877664] AN
This is a randomised, double -blind, placebo -controlled, parallel- group multinational , 
multicentre phase III study . The subjects will be allocated to 2 parallel groups receiving either 
levosimendan 1-2 mg daily or placebo in 2:1 ratio.The study  will be conducted globally . The 
estimated number of sites will be approximately 100.
The total duration for double -blind comparison will be 48 weeks. A futility /interim analysis will 
be conducted when approximately  50% and all of the subjects have been treated for 12weeks. 
An independent data and safet y monitoring board (DSMB) will be established for this and for 
safet y monitoring purpose s.
There will be a screening visit, a baseline visit (V1) followed b y visits a t 2 weeks (V2), 4 weeks 
(V3), 8 weeks (V4), 12weeks (V5), 24 weeks (V6), 36 weeks (V7) and 48 weeks (V8), and 
telephone contacts during weeks 18, [ADDRESS_877665] 
after visit 3 and after later visits (see section 5.3.2 ). The total study duration for each subject will 
be about 51-52 weeks including the end-of-study visit. The study design is presented inFigure 
1.
Figure 1.Study  design
4-14 d
1Dose will be increased if the 1 mg/daydosing was well tolerated
2Dose can  be decrea sed back to 1 mg/dayif required for any reason In case the dose was decreas ed due to 
HR increase > [ADDRESS_877666] after approx 2 weeks
3Any time during the week2 wks 
± 3 d14-25 dV1
Baseline V21V32V52V72 End-of-study 
visit
36 wks
± 5 dV62
24 wks
± 5 d12 wks
± 5 d4 wks
± [ADDRESS_877667]-treatment
period Screening
Placebo
V42
8 wks
± 5 dV8
48 wks
± 5 dLevosimendan 
1 mg/day
TC3TC3TC3
18 wks 30 wks 42 wksLevosimendan 
2 mg/day
4.SELECTION OF S TUDY POPULA TION
4.[ADDRESS_877668] meet all of the following criteria to be included into the study :
DNO 090017ff823c9bac  /  . 19 / 58 DNO 090017ff823c9bac Approved  /  1.0 19 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
1.Written or verbal informed consent (IC) for participation in the study  will be obtained from 
the subject. In case that the study  subject him/herself cannot sign the IC due to severe muscle 
weakness, a witness may sign the consent form to indicate that the subject has given verbal 
consent.
2.Age at least 18 years.
3.Male or female subjects with diagnosis of laboratory  supported probable, probable or 
definite ALS according to El Escorial revised criteria (Brooks BR et al., 2000 ). Full 
electrom yogram (EMG) report available consistent with AL S (but not necessarily fulfilling 
the electrodiagnostic criteria for AL S) from an experienced neurophy siologist.
4.Able to swallow study  treatment capsules , and in the opi[INVESTIGATOR_871], is expected 
to continue to do so during the stud y.
5.Sitting SVC between 60-90 % of the predicted value for age, height and sex at screening 
visit.
6.Disease duration from symptom onset (defined by  [CONTACT_654211]) 12-
48 months at the time of visit 1 (baseline). 
7.Able to perform supi[INVESTIGATOR_654162] b y the investigator.
8. Subjects with or without riluzole and/or edaravone . If using riluzole (any daily  dose up to 
100 mg), the dose must have been stable for at least [ADDRESS_877669] 4 weeks before the screening visit (at least one 28-day treatment cycle as 
indicated) and should not be changed during the study .If not on riluzole and/or edaravone , 
the respective treatments should not bestartedduring the study .
4.3 Exclusion criteria
Subjects will not be included into this study  if they meet any  of the following criteria:
1. Subject in whom other causes of neuromuscular weakness have not been excluded.
2. Subject with a diagnosis of another neurodegenerative disease (e.g. Parkinson’s or 
Alzheimer’s disease).
3.Assisted ventilation of any t ype within 3 months before thescreening vi sit or at screening.
4.Any use of a diaphragm pacing sy stem (DPS) within 3 months before the screening visit.
5.Any form of stem cell or gene therapy  for the treatment of AL S.
6.Known hy persensitivity  to levosimendan.
7.Administration of levosimendan within 3 months before the screening visit or previous 
participation in the present phase III study  or earlier study  with oral levosimendan in ALS 
patients (LEVALS). 
8.Any use of tirasemtiv or reldesemtiv within 1 month before the screening visit.
DNO 090017ff823c9bac  /  . 20 / 58 DNO 090017ff823c9bac Approved  /  1.0 20 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
9. Participation in a clinical trial with any experimental treatment within 30 days or within 5
half-lives of that treatment (whichever is longer) before the screening visit.
10.Any botulinum toxin use within 3 months before the screening visit. 
11.Recorded diagnosis or evidence of major psychiatric diagnosis, significant cognitive 
impairment or clinicall y evident dementia that may interfere with the patient’ s ability  to 
comply  with study  procedures.
12.Pulmonary  illness (e.g. asthma or COPD) requiring re gular treatment.
13.Haemod ynamically significant uncorrected valve disease or hypertrophic cardiomy opathy 
or restrictive cardiom yopathy. 
14.Any cardiovascular event (e.g. myocardial infarction, HF, arrhythmia or stroke) requiring 
hospi[INVESTIGATOR_654163] 3 months before the screening visit.
15.History  of Torsades de Pointes (TdP) or diagnosed long QT- syndrome.
16.History  of life-threatening ventricular arrhy thmia, unless treated with reliable measures to 
prevent recurrence (e.g. with placement of implantable cardioverter defibrillator [ICD]or 
catheter ablation).
17.History  of second or third degree atrioventricular (AV) block or sinus node disease at 
screening, if not treated with pacemaker.
18.HR repeatedly > [ADDRESS_877670] at screening. If the HR 
is > [ADDRESS_877671] to confirm HR > 100 bpm.
19.Systolic blood pressure (SBP) < 90 mmHg at screening .
20.Potassium < 3.7 mmol/l or > 5.5 mmol/l at screening.
21.Severe renal impairment (creatinine clearance < 30 ml/min at screening ),creatinine > 
170µmol/l at screening or on dialy sis.
22.Blood haemoglobin < 10 g/dl at screening or blood donation or loss of significant amount 
of blood within 60 day s before the screening visit.
23.Clinically  significant hepatic impairment at the discretion of the investigator.
24.Body mass index ( BMI )≤ 18.5kg/m2(BMI = weight/height2).
25.Women who are lactating orof reproductive age without a negative pregnancy  test and 
without a commitment to using a highl y effective method of contraception (e.g. oral 
hormonal contraceptives associated with inhibition of ovulation, intrauterine devices and 
long acting progestin agents), if sexually  active during the study , and for [ADDRESS_877672] dose of the study  treatment. Women who are postmenopausal ([ADDRESS_877673] 
menstrual cycle), surgically  sterilised or who have undergone a hysterectomy  are considered 
not to be reproductive and can be included.
26.Patient judged to be actively  suicidal by [CONTACT_654212] 3 months before the 
screening visit .
DNO 090017ff823c9bac  /  . 21 / 58 DNO 090017ff823c9bac Approved  /  1.0 21 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
27.Patients with known history  of human immunodeficiency  virus (HIV) infection.
28.Any other clinic ally significant cardiovascular , gastrointestinal, hepatic, renal, neurological 
or psychiatric disorder or any other major concurrent illness that in the opi[INVESTIGATOR_654164] a health 
risk for the subject if he/she took part in the study .
4.4 Information collected on screening failures
For subjects screened but not included in the study, the following case report for ms (CRFs) will 
be completed: date of the screening visit, IC, demography  (birth year , age, sexand race), criteria 
causing the exclusion and decision of entry . In addition, all information (including concomitant 
treatments and medical history ) about AEs related to study  assessments and SAEs must be 
collected. If according to the source data there are no AEs, the AE CRF canbe inactivated. 
4.[ADDRESS_877674] discontinue the study  treatment for the followi ng reasons: 
HR increase of > 30 bpm from baseline (visit 1) at the dose level of 1 mg once daily in 
3 separate ECG recordings , taken within 5-10 minutes from each other before the 
morning dose of the study drug (see also section 6.5.4 ).
Life-threatening supraventricular or ventricular arrhy thmia .
The investigator judges that it is in the best interest of the subject to stop the study 
treatment due to any other abnormalit y compromising patient safety . However, the 
investigator should consult the medical monitor whenever possible in these instances.
Pregnancy .
Invasive mechanical ventilation by  [CONTACT_654213] y. 
The subjects who have discontinued the study medication, but continue in the study , are 
encouraged to follow the study visit and phone call schedule according to the study protocol for 
recording ALSFRS -R, ventilatory  support and survival status. End-of- study  visit assessments 
for these subjects will be performed [ADDRESS_877675] those of safety , should be performed, preferably  according to the schedule for the end -of-
study  assessments.
The study  monitor should be notified about premature discontinuations by[CONTACT_6968]/phone/fax 
within 24hours in the event of discontinuation due to anSAE (see section [IP_ADDRESS] )or within 
7daysin the event of discontinuation due to another reason.
DNO 090017ff823c9bac  /  . 22 / 58 DNO 090017ff823c9bac Approved  /  1.0 22 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
Subjects who prematurely discontinue will not be replaced. Discontinued subjects are not 
allowed to re -enter the study .
5.STUDY TREATMENTS
Manufacturing, packaging, and labelling of the study  treatments will comply  with good 
manufacturing practice (GMP) regulations (Annex 13 of EU guide to GMP). The capsules will 
be stored below 30C and the container kept tightly  closed.
5.[ADDRESS_877676]
Placebo Levosimendan capsule for oral administration containing onl y excipi[INVESTIGATOR_840].
5.3 Dosing
5.3.1 Selection and timing of doses
The subjects will be randomised centrall y to receive eith er levosimendan or placebo. The daily 
dose of oral levosimendan will be 1-2 mg (see section 5.3.2 ). The subjects will take the study  
treatment in the morning and whenthe dose isincreased to [ADDRESS_877677] . The prescribed time of the second dose will be recorded in the CRF and should be the 
same each day unless changed by [CONTACT_093]. It is recommended to take the study  treatment 
about 1 hour before food intake or on an empty  stomach. The mo rning dose of study  treatment 
will be administered at the study  centre during the visit day s.
The total duration of study  treatments will be 48 weeks.
5.3.2 Dose adjustment
The daily  doses of oral levosimendan will be 1-2 mg depending on the tolerability  (mainl y 
judged b y HR). The subjects will start with a 1 mg dose (in the morning) for 2 weeks. 
HR will be assessed in the morning before study  drug intake :
At visit 2 (2 weeks) :
-If the HR in the 12- lead ECG has increased ≤ [ADDRESS_877678] will 
increase the dose to 1 mg b.i.d.
-If the HR in the 12 -lead ECG has increased > [ADDRESS_877679] will continue with the 1 mg once daily . If the increase in HR is > [ADDRESS_877680] discontinue the study  treatment (see section 
4.5).
DNO 090017ff823c9bac  /  . 23 / 58 DNO 090017ff823c9bac Approved  /  1.0 23 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
At visit 3 (4 weeks) or later visits:
-If the HR in the 12-lead ECG has increased ≤ 20 bpm from baseline, no changes to 
the dosing regimen are made .
-If the HR in the 12-lead ECG has increased > [ADDRESS_877681] will decrease the 
dose back to 1 mg once daily if treated with 1 mg b.i.d. I n case the increase in HR is 
> [ADDRESS_877682] be checked again 
at an additional visit approximately  2 weeks after the dose decrease. If the increase 
> [ADDRESS_877683] discontinue the study  treatment (see section 4.5) .
Administration of placebo (1 or 2 capsules per day) will be based on the same criteria as
described for levosimendan above.
5.4 Method of assigning study  subjects to treatment groups
The study  subjects will be randomly  allocated to treatment groups by[CONTACT_325513] (IWRS) using a complete randomisation scheme to eliminate the possible bias due to 
predictability  of treatment assignment (Hewitt CE et al., 2006 ).The s ubjects will be allocated at 
random to the levosimendan andplacebo groups at aratio of 2:1using permuted blocks .
The subjects will be stratified via IWRS for bulbar and spi[INVESTIGATOR_654165], use of edaravone
and in regard togeographical region for Northern America vs. regions outside Northern 
America , so that in these groups the treatment allocations will be balanced. Stratification will 
occur on a stud y level rather than on a centre level. Enrolment by  [CONTACT_654214].
To ensure random allocation of the study  treatments, all subjects to be randomly  allocated will 
receive the treatment that corresponds to the next consecutive subject number.
5.[ADDRESS_877684] access to the treatment code. The treatment code will be opened after the 
study  database has been locked.
5.6 Emergency  procedures
In case of an emergency  requiring immediate knowledge of the study  treatment, the treatment 
code may be broken by [CONTACT_654215]. As a back -up to the IWRS,there will 
be a 24x7x365 Customer Help Desk available to support the investigators in unblinding . 
Whenever possible, the investigator should discuss the case with themedical monitor prior to 
unblinding .If not possible, the medical monitor should be notified immediately  after breaking 
the treatment code.
DNO 090017ff823c9bac  /  . 24 / 58 DNO 090017ff823c9bac Approved  /  1.0 24 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
The sponsor’s personnel may unblind the treatment assignment for an individual subject’s SAE 
in order to fulfil expedited regulatory  reporting r equirements.
5.6.[ADDRESS_877685] within 30 days before t he screening visit.The use of tirasemtiv or reldesemtiv
within 1 month or botulinum toxin within 3 months before the screening visit is prohibited.
5.7.1 Prohibited treatments during the study
The use of tirasemtiv orreldesemtiv isprohibited during the study  due to their similar 
mechanism of action with levosimendan.
The subjects should avoid starting supplements (such as creatine, N-acetyl-cysteine, coenzy me 
Q10) as well as off -label uses of drugs for ALS (such as memantine and tamoxifen) d uring the 
study .
Use of botulinum toxin is not allowed during the study .
If the permissibility  of a specific drug/treatment is questionable, the medical monitor must be 
contact[INVESTIGATOR_530].
5.7.[ADDRESS_877686] 4 weeks before the screening visit (at least one 28-day treatment cycle as 
indicated) and should not be changed during the study . If not on riluzole and/or edaravone , the
respective treatment (s)should not be startedduring the study . If riluzole and/or edaravone needs 
to be discontinued due to an AE, the medical monitor must be contact[INVESTIGATOR_530].
If necessaril y required, benzodiazepi[INVESTIGATOR_654166] e.g. panic attacks 
or anxiety .
Any other treatments, with the exceptions noted in section 5.7.[ADDRESS_877687]’s welfare, and which will not interfere with the study  treatment, may  be given at 
the dis cretion of the investigator.
If the permissibility  of a specific drug/treatment is questionable, the medical monitor must be 
contact[INVESTIGATOR_530].
DNO 090017ff823c9bac  /  . 25 / 58 DNO 090017ff823c9bac Approved  /  1.0 25 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877688] maintain accurate records 
demonstrati ngthe date and amount of study  treatments received, to whom and by [CONTACT_654216] (drug dispensing list) and accounts ofstudy  treatments accidentally  or deliberatel y 
destroy ed. 
At the end of the study , any remaining study  treatments will be collected and returned to the 
sponsor. Any  discrepancies between the returned and expected returned study treatments 
should 
be explained.
5.[ADDRESS_877689] has completed 48 
weeks of treatment and the end -of-study  visit of the current study , either in the form of an open -
label extension study  or compassionate use program.
6.STUDY PROCEDURES A ND ASSESSMENTS
6.1 Stud y procedures
Table 1lists all study  procedures and indicates with an ‘x’during which visit a particular 
procedure is performed.
DNO 090017ff823c9bac  /  . 26 / 58 DNO 090017ff823c9bac Approved  /  1.0 26 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877690]-
treatment 
period
Scr. visit
4-14 d 
before V1V1
Baseline D1V2
Week 2
D15 ± 3 dV3
Week 4
D29 ± 3 dV4
Week 8
D57 ± 5 dV5
Week 12
D85 ± 5 dTC 
Week 
18V6
Week 24
D169 ± 5 dTC 
Week 
30V7
Week 36
D253 ± 5 dTC 
Week 
42V8
Week 48
D337 ± [ADDRESS_877691] for females of 
childbearing potentialx x x x x x x x x
Testing ability to swallow 
capsulesx
SVC sitting x
SVC supi[INVESTIGATOR_050] x x x x x x x x x x
Eligibility criteria and decision 
of entryx
Study treatment x
ALSFRS -R x x x x x x x x x x
CGI x x x x x x
DNO 090017ff823c9bac  /  . 27 / 58 DNO 090017ff823c9bac Approved  /  1.0 27 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877692]-
treatment 
period
Scr. visit
4-14 d 
before V1V1
Baseline D1V2
Week 2
D15 ± 3 dV3
Week 4
D29 ± 3 dV4
Week 8
D57 ± 5 dV5
Week 12
D85 ± 5 dTC 
Week 
18V6
Week 24
D169 ± 5 dTC 
Week 
30V7
Week 36
D253 ± 5 dTC 
Week 
42V8
Week 48
D337 ± 5 dEnd-of-
study visit 
14-25 d 
after V81
Borg CR10 scale x x x x x x x x x
Epworth Sleepi[INVESTIGATOR_7110] (ESS) x x x x x x
Pi[INVESTIGATOR_2272] 
(PSQI)x x x x x x
Use of health care and home 
care resources and non -medical 
assistive devicesx4x x x x x x x
Blood sampling for 
levosimendan, OR -1855 and 
OR-1896 PKx x x x x x x
Blood sampling for riluzole PK x x x x
Blood sampling for exploratory 
biomarkersx x x x x x x
Assessment of suicidality x x x x x x x x x x
Blood sampling for PG x5
Status for NIV support, invasive 
mechanical ventilation by 
[CONTACT_654217] x
Medical history and current 
medical conditionsx
Concomitant treatments x
1Also for subjects who discontinue treatment but continue in the study, end -of-study visit assessments will be performed 14- 25 d after the laststudy treatment administration
23 baseline recordings pre -dose
3Except thyroid -stimulating hormone (TSH)
4Data requested for the past 7 days prior to baseline visit 
5One sample during the study preferably at visit 1 (baseline)
DNO 090017ff823c9bac  /  . 28 / 58 DNO 090017ff823c9bac Approved  /  1.0 28 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877693] an opportunity  to ask questions and sufficient time to decide whether or not to participate 
in the study . A signed and dated written IC will be obtained (a witness may sign the consent 
form to indicate that the subject has given verbal consent).
Re-screening (one occasion, unless otherwise authorised by  [CONTACT_1689]) is allowed for 
example in case the patient has been taking prohibited treatment within 3 months before the 
screening visit or the si tting SVC is not within the inclusion criterion limits (60- 90%).
The following procedures will be performed at the screening visit to ensure fulfilling the 
inclusion/exclusion criteria:
Demographic data ( birth year, age, sex, race, geographic region) andweight and height 
will be recorded. BMI will be derived from weight and height automaticall y in electronic 
case report form (eCRF).
ALS history (date of diagnosis, ALS famil y history, site of onset [spi[INVESTIGATOR_1304]/bulbar] and start 
date of ALS s ymptoms) will be recorded.
HR and BP will be recorded in supi[INVESTIGATOR_2547].
12-lead ECG will be recorded in supi[INVESTIGATOR_2547].
Physical examination will be performed.
A blood sample for haematology , clinical chemistry  and serology  will be collected and 
a urine sample will be collected for urinal ysis. A pregnancy  test will be performed for 
females of childbearing potential.
Ability  to swallow capsules will be tested with a placebo capsule.
SVC will be measured in the sitting and supi[INVESTIGATOR_2547] s.Sitting SVC% will be assessed 
first and used for inclusion criterion. Thereafter, SVC supi[INVESTIGATOR_654167].
Status for NIV support, i nvasive mechanical ventilation by [CONTACT_654213] y 
and survival will be recorded.
AEs will be inquired.
Medical history , current medical conditions and concomitant treatments will be recorded.
Suicidality  will be as sessed.
6.1.2 Procedures during the treatment period
Procedures during visit 1 (baseline) are presented in Table 2and procedures during visits 2 -8 in 
Table 3. The morning dose of study  treatment will be administered at the study  centre during the 
visit day s.
DNO 090017ff823c9bac  /  . 29 / 58 DNO 090017ff823c9bac Approved  /  1.0 29 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
Table 2. Procedures at visit 1 (baseline)
Time Pre-dose [ADDRESS_877694] 7 days prior to baseline visit
4One sample during the study preferably at visit 1
DNO 090017ff823c9bac  /  . 30 / 58 DNO 090017ff823c9bac Approved  /  1.0 30 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877695] for females of childbearing potential x4
SVC supi[INVESTIGATOR_050] x
Study treatment x
ALSFRS -R x1
CGI x3
Borg CR10 scale x
ESS x3
PSQI x3
Use of health care and home care resources use and non -medical 
assistive devicesx
Blood sampling for lev osimendan, OR -1855 and OR -1896 PK x x5
Blood sampling for riluzole concentration x5
Blood sampling for exploratory biomarkers x1
Assessment of suicidality x
Status for NIV support, invasive mechanical ventilation by [CONTACT_654218] x
Medical history and current medical conditions x
Concomitant treatments x
1Not at visit 2
2Except TSH
3Not at visits 2 and 4
4Not at visit 2
5 Not at visits 4, 5, 6 and 7
6.1.3 Telephone contacts
The study  centre personnel will phone the subjects during weeks 18, 30 and 42. During the phone 
call AL SFRS -R will be assessed and AEs inquired.
6.1.4 Additional visits
Additional visits will be performed in case dose decreases were triggered by [CONTACT_654219] (see section 5.3.2 ). Additional visits may take place approximately  2 weeks after 
the dose decre ase.Procedures during additional visits are present ed in Table 4.
DNO 090017ff823c9bac  /  . 31 / 58 DNO 090017ff823c9bac Approved  /  1.0 31 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877696]. The following procedures will be performed:
HR and BP will be recorded.
12-lead ECG will be record ed.
SVC supi[INVESTIGATOR_654168].
The Borg CR10 scale to assess the intensity  of dyspnoea will be completed at rest in 
sitting and supi[INVESTIGATOR_105523] (immediately  before SVC measurement).
Physical examination will be performed.
Weight will be recorded.
A blood sample for haematology  and clinical chemistry  and a urine sample for urinaly sis 
will be collected. A pregnancy  test will be performed for females of childbearing 
potential.
AEs, current medical conditions and concomitant treatments will be recorded .
Status for NIV support, invasive mechanical ventilation by [CONTACT_654213] y 
and survival will be recorded
Suicidality  will be assessed.
6.1.[ADDRESS_877697] discontinued the study medication, but continue in the study , are 
encouraged to follow the study visit and phone call schedule according to the study protocol for 
recording ALSFRS -R, ventilatory  support and survival status.
6.2 Efficacy assessments
6.2.1 Slow Vital Capacity
The primary efficacy variable will be the change from baseline at 12 weeks in SVC measured in 
the supi[INVESTIGATOR_2547], SVC (supi[INVESTIGATOR_050]). All SVC measurements prior to [ADDRESS_877698] read from 3 attempts will be chosen. The volume is measured in 
litres and the SVC variable will be % of predicted (normal) value for age, height and sex. In 
DNO 090017ff823c9bac  /  . 32 / 58 DNO 090017ff823c9bac Approved  /  1.0 32 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
addition, time to decline in supi[INVESTIGATOR_654169]  ≥20% and time to supi[INVESTIGATOR_654129] ≤ 50%
of predicted will be assessed. 
SVC (supi[INVESTIGATOR_050]) will be assessed once at each visit during the study including the baseline (visit1), 
i.e. in the morning before the study  treatment administration .
SVC will be assessed in the sitting and supi[INVESTIGATOR_654170]. Sitting SVC will be 
one of the inclusion criteria. Supi[INVESTIGATOR_654171] .
6.2.2 Revised A LS Functional Rating Scale
ALSFRS -R(Cedarbaum JM et al., 1999 )will be assessed. This scale includes 12 items: speech, 
salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, 
turning in bed and adjusting sheets, walking, climbing stairs, dyspnea, orthopnea, and respi[INVESTIGATOR_27580] . Each item will be scored from 0 to 4. The variables derived will be the scores of 
the 12 separate items, the total scores of each subdomain (bulbar, fine motor, gross motor and 
respi[INVESTIGATOR_696] ) and the total score of AL SFRS -R. 
In addition the following variables will be assessed:
Combined assessment of function and survival (CAFS)
Change from baseline in A LSFRS-R total score
Time to decline from baseline in AL SFRS -R total score b y ≥ 20% 
Time to decline from baseline in the respi[INVESTIGATOR_654172] -R (items 10, 11, and 
12).
6.2.3 Time to respi[INVESTIGATOR_654173] ‘Time to respi[INVESTIGATOR_654124]’ composite endpoint will be used to validate the changes seen in 
supi[INVESTIGATOR_654129]. This variable consists of the following events:
At least 1 point decrease in AL SFRS -R respi[INVESTIGATOR_654174] 10, 11 or 12
Meeting ‘protocolis ed’ criteria for NIV: supi[INVESTIGATOR_654129] ≤ 50% predicted
Starting NIV (actual start or attempt to start NIV)
Invasive mechanical ventilation by  [CONTACT_654213] y or death.
Time to respi[INVESTIGATOR_654175] [ADDRESS_877699] met.
6.2.4 Clinical Global Impression
CGI is used to rate the severity  of subjects ’clinical condition . Clinical condition is assessed by 
[CONTACT_654220] a VAS . Score of 0 indicates (in the 100 millimetre scale) that the 
subject is completel y well without any disability and score of [ADDRESS_877700] the average clinical condition during the week.
DNO 090017ff823c9bac  /  . 33 / 58 DNO 090017ff823c9bac Approved  /  1.0 33 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
6.2.5 Borg Category  Ratio 10 Scale
Borg Category  Ratio 10 (CR10) scale will be used in the assessment of dyspnoea (Borg GA, 
1982 ).The subjects willbe asked topoint outa score quantify ing their perception on the intensity
of dyspnoea on the CR10 scale at rest insitting and supi[INVESTIGATOR_105523] (immediatel y befor e SVC 
measurements ).Orthostatic changes between sitting and supi[INVESTIGATOR_654176].
6.2.6 Epworth Sleepi[INVESTIGATOR_654177] (Johns MW, 1991 ).The ESS is a self-
administered questionnaire with 8 questions. Subjects are asked to rate, on a 4 -point scale (0 -3), 
their usual chances of dozing off or falling asleep while engaged in eight different activities. 
Score 0 indicat es‘no chance of dozing’ and 3 indicat es‘high chance of dozing’ .Most people 
engage in those activitie s at least occasionall y, although not necessarily  every day. If onehas
not engage drecentl y ina certain activit y, the subject will estimate how sleepy  he/she would 
have been during that activity . The ESS score (the sum of 8 item scores, 0 -3) can range from [ADDRESS_877701]’s average daytime sleepi[INVESTIGATOR_008].
The s um score 10 or more suggests medical attention may be required.
6.2.7 Pi[INVESTIGATOR_654178] a self-rated questionnaire which assesses sleep quality  and disturbances over a preceding 
1 month period (Buysse DJ et al., 1 989). There are a total of 19 self- rated questions/items which 
are included in the scoring. These 19 items are combined to form seven component scores 
(subjective sleep quality , sleep latency , sleep duration, habitual sleep efficiency , sleep 
disturbance s, use of sleepi[INVESTIGATOR_88794], day time dy sfunction) each of which has a range of 0 -
3 points. In all components, a score of 0indicates no difficulty ,while a score of 3indicates 
severe difficult y. The seven component scores are then added to yield one global score , with a 
range of 0 -21 points, 0 indicating no difficulty  and 21 indicating severe difficulties in all items.
The derived variable will be the PSQI global score. Global score of >[ADDRESS_877702] in use atbaseline ,are recorded and thereafter all new devices that they start 
using due to AL S will be recorded in the diary each week . Regarding home care, the diary  will 
contain information of the number of formal (paid /public services ) andinformal (unpaid e.g.by
[CONTACT_221349], other famil y members, friends or other volunteers ) home care hours received. 
Additionally , information will be collected about the number of times such home care has been 
received during the night time. Details of the home diary  will be descri bed in a separate 
document.
DNO 090017ff823c9bac  /  . 34 / 58 DNO 090017ff823c9bac Approved  /  1.0 34 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877703]’s status for NIV support, invasive mechanical ventilation by [CONTACT_654213] y 
and survival will be recorded at all visits.
6.[ADDRESS_877704] time at visit 2 (2 weeks) and thereafter 
during all consecutive visits (except atend-of-study  visitand possible additional visits ). The 
samples will be collected in the morning after study  drug intake (Table 5).
Table 5. Blood sampl ing for the determination of levosimendan and its metabolites 
concentrations
Blood samplingVisit
V2
Week 2V3
Week 4V4
Week 8V5
Week 12V6
Week 24V7
Week 36V8
Week [ADDRESS_877705] sample after dosing 
(min) 30-90 30 -90 30 -90 30 -90 30 -90 30 -90 30 -90
Second sample after 
dosing (min)120-240 120- 240 - - - - 120-240
Blood samples will be collected also to measure trough concentrations of riluzole before study 
treatment dosing at baseline and at visits 2, 3 and 8.
Instructions for the collection, handling, storage and transportation of samples will be provided 
before the start of the study .
6.3.2 Determination of levosimendan, OR -1855 and OR -1896 concentrations in plasma
The concentrations of levosimendan, OR- 1855 and OR -1896 in plasma will be determined with 
a validated liquid -chromatograph y-tandem mass spectrometry  (LC-MS/MS) method.
Bioanal ytical details and criteria for acceptance of the results will be described in the 
bioanaly tical plan and reported in the bioanal ytical report.
6.3.3 Determination of riluzole concentrations in plasma
The concentrations of riluzole in plasma will be determined with a validated LC-MS/MS
method.
Bioanal ytical details and criteria for acceptance of the results will be described in the 
bioanaly tical plan and reported in the bioanal ytical report.
6.3.4 Calculation of pharmacokinetic variables
Due to the sparse blood sampling, no PK variables will be calculated. However, plasma 
concentrations of levosimendan , OR-1855 and OR-1896 after the morning dose ofthe study 
DNO 090017ff823c9bac  /  . 35 / 58 DNO 090017ff823c9bac Approved  /  1.0 35 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
treatment atvisit 2 (2 weeks) and thereafter during all consecutive visits (exc luding the end -of-
study  visit) and plasma concentrations of riluzole before study  treatment dosing at baseline (visit 
1) and at visit 2, visit 3 and visit 8 will be collected.
6.4 Biomarker, pharmacogenomic and other specific biological 
variables
6.4.1 Biomarker s
Spare plasma taken originally  for the analy sis of levosimendan and its metabolites may  be used
for exploratory  research purposes. The plasma samples will be stored in the sponsor’s sample 
repository  to allow possible exploratory  biomarker analyses related to the disease state of the 
subjects and the pharmacody namics of levosimendan.
A 5 ml blood sa mples will be collected before dosing at visits 1, 3, 4, 5, 6, 7 and 8. The samples 
may be used for exploratory  biomarker analysesthat may give supportive data related to the 
disease state of the subjects.
Instructions for the collection, handling, storag e and transportation of samples will be provided 
before the start of the study .The plasma samples will be stored in the sponsor’s sample 
repository  until analy sis.
6.4.2 Pharmacogenomics
A 5 ml blood sample for DNA extraction will be taken once during the study preferabl y atvisit 1
(baseline) .
Uses of the extracted DNA sample are:
1.Determination of subject’s acety lation status (NAT polymorphisms). This will be 
determined from all subjects participating in the study  and the results will be source data. 
The sample s will be destroy ed [ADDRESS_877706] has signed the PG I C.
The PG assessment is done as exploratory  research. The objective of the PG research is to assess 
whether genetic polymorphisms relate to the absorption, distribution, metabolism, excretion, 
pharmacod ynamics or safet y of levosimendan. The extracted DNA will be stored in the 
sponsor ’sDNA repository  for future use. 
Instructions for the collection, handling, storage and transportation of samples will be provided 
before the start of the study .
DNO 090017ff823c9bac  /  . 36 / 58 DNO 090017ff823c9bac Approved  /  1.0 36 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
6.5 Safet yassessments
6.5.1 Adverse events
[IP_ADDRESS] Definitions
An AEis any untoward medical occurrence in a study  subject administered a pharmaceutical 
product and which does not necessaril y have a causal relationship with this treatment. An AE 
can therefore be any unfavourable and unintended sign (including an abnormal laboratory  
finding), symptom, or disease temporally  associated with the use of an investigational medicinal 
product, whether or not related to the investigational medicinal product. The definition also 
covers medication errors and uses outside what is fores een in the protocol, including misuse and 
abuse of the product.
Thus, an AE may be an appearance or worsening of any undesirable sign or symptom, any 
worsening of the current medical conditions or onset of a new disease, compared with the 
previous observat ions or a clinically significant adverse change in a laboratory variable or other 
diagnostic finding (e.g. ECG).
In this study , day-to-day fluctuation in ALS signs/s ymptoms (e.g. dysphagia, muscular 
weakness) not indicating clinically  significant progressi on of the disease should not be reported 
as an AE.
AnSAE is any  untoward medical occurrence s that at any  dose
results in death
is life -threatening
requires inpatient hospi[INVESTIGATOR_15574] (see section 
[IP_ADDRESS] for exclusions)
results in persistent or significant disability /incap acity  
is a congenital anomal y/birth defect , or
is an important medical event jeopardizing the patien tor requiring interventi on to prevent 
a serious outcome (examples of such events are intensive treatment in an emergency 
room or at home for allergic bronchospasm; blood dy scrasias or convulsions that do not 
result in hospi[INVESTIGATOR_11956]; development of drug dependency  or drug abuse ; overdose or 
interaction) .
Other significant AEs are AEs (other than those meeting the definition of serious) that are of 
clinical importance and lead to:
adiagnos tic or therapeutic intervention
discontinuation of the investigational medicinal product
reduction of its dose
significant a dditional concomitant treatment , or
DNO 090017ff823c9bac  /  . 37 / 58 DNO 090017ff823c9bac Approved  /  1.0 37 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
marked haematological and other laboratory  abnormalities
[IP_ADDRESS] Assessment of adverse events
All AEs must be elicited, documented and reported by [CONTACT_654221] a study  subject signs the IC form until the end-of-study  visit (14-25days after the last 
study  treatment administration ). 
SAEs and other significant AEs should be followed up until resolved or until the event is 
considered a chronic or stable outcome, or both.
An A E may be notified to the investigator by [CONTACT_232304] (or his/her caregiver )or observed 
by [CONTACT_654222] , or be an adverse change in laboratory  assessment results. The 
investigator will evaluate the subject’s AEs at each visit by [CONTACT_7939] a standard question such as 
“Since you were last asked, have you felt unwell or different from the usual in any way?”
The investigator will assess and record the causality  and severity  of the AEs. Causality  should 
be assessed in relation to the investigational medicinal product (see criteria for causality  and 
severit y below).
Causality  criteria:
Related: The tempora l relationship of the AE/SAE onset to the administration of the 
investigational medicinal product makes a causal relationship possible, and other drugs, 
therapeutic interventions or underl ying conditions do not provide a sufficient explanation for the 
AE/S AE.
Not related: The temporal relationship of the AE/SAE onset to the administration of the 
investigational medicinal product makes a causal relationship unlikely, or other drugs, 
therapeutic interventions or underl ying conditions provide a sufficient explanation for the 
AE/SAE.
Severity  criteria:
Mild: Discomfort noticed, but it does not affect normal activity .
Moderate: Discomfort sufficient to reduce or affect normal daily  activity .
Severe: Incapacitating with inability  to work or perform normal dail y activity .
From the time that a study subject candidate signs the IC form ,newl y appearing diagnosed 
diseases will be recorded on the AE CRF.
Investigators must report allAEs to the sponsor on a specific AE CRF irrespective of their 
assessment of the causal relationship of the investigational medicinal product to the event.
[IP_ADDRESS] Reporting of serious adverse events by [CONTACT_654223] [ADDRESS_877707] to 
the event.
DNO 090017ff823c9bac  /  . 38 / 58 DNO 090017ff823c9bac Approved  /  1.0 38 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
In this stud y, the following events will not be reported as SAEs:
hospi[INVESTIGATOR_654179] -existing condition that has not 
exacerbated during the study
hospi[INVESTIGATOR_654180]/or evaluation sin connection with ALS such as 
evaluation for the need or ini tiation of ventilatory  support (e.g. NIV) or gastrostomy .
All SAEs should be reported electronic allyby [CONTACT_654224]. Optionally , if the investigator is not able to submit
the SAE electronically, apaper version of the SAE form can be completed and sent by e -mail or 
fax.The SAE reporting contact [CONTACT_654225]’s study  file.
If the initial report is reported b y phone or e -mail to the study monitor or other contract research 
organisation (CRO ) personnel and the study  centre personnel are unable to fill in the SAE 
elect ronically within [ADDRESS_877708] report the SAE electronical lyas soon as possible. 
The minimum criteria for SAE reporting are: the event or outcome meets the SAE definition, 
the event happens to an identifiable study  subject, and the event is reported by [CONTACT_654226] (usually  an investig ator or other qualified study  centre personnel)
A follow -up report to an SAE should be prepared if any  relevant change in the condition of the 
study  subject occurs after the initial report. The follow -up report should be documented as an 
update to the init ial report.
SAEs that occur after the end-of-study  visit(14-[ADDRESS_877709] study  treatment 
administration) ,should be reported if the investigator feels that there is a reasonable possibility  
for the event to have been caused b y the study  subject’ s participation in the study . 
[IP_ADDRESS] Reporting of serious adverse events to competent authorities and ethic scommittees
The sponsor is responsible for expediting all suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) as well as other safet y issues requiring expedited reporting to the relevant authorities 
within applicable timelines. These tasks can also be carried out by  a delegate of the responsible 
sponsor.
Notification of the ethics committees ( ECs) and institutional review boards (IRBs )about all 
relevan t events (S[LOCATION_003]Rs, other relevant safet y information) will be performed by [CONTACT_654227]/or by [CONTACT_654228] .
The Sponsor will inform all investigational sites about suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) as well as other safet y issues according to all applicable regulations.
The expectedness evaluation is required for regulatory  reporting and it is performed by [CONTACT_103] . The expectedness in this study  is eval uated against the Reference safety  information 
section in the current ODM -109: oral levosimendan capsule for treatment of ALS investigator’s 
brochure.
DNO 090017ff823c9bac  /  . 39 / 58 DNO 090017ff823c9bac Approved  /  1.0 39 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
6.5.2 Special situations
Special situations with study  treatment are defined as: 
medication error
overdose
abuse
misuse
interaction
These special situations with study  treatment are reported on the Special situations with study  
treatment CRF even if there is no accompan ying AE. All clinical manifestations in relation to 
these special situations will be reported as AEs or SAEs at the same time using the corresponding 
section of the CRF.
6.5.[ADDRESS_877710]’s or the partner’s consent. A pregnancy  follow -up form 
will be provided to the investigator forcompletion after the sponsor has received the initial 
report.
Any case of pregnancy during a clinical study should be reported by [CONTACT_654229].
6.5.4 Clinical safety assessments
Vital signs (HR, systolic and diastolic BP) and standard 12-lead ECG will be assessed at 
screening, at each visit during the treatment period before and 30-[ADDRESS_877711]. Subjects will then be asked to stand up and after 3 minutes, standing HR and BP 
will be measured (orthostatic test). In case the subject is not able to stand, only supi[INVESTIGATOR_654181].
A standard 12- lead ECG (central r eading) will be recorded with subject ly ing supi[INVESTIGATOR_145279] a 
5-minute rest. 3 baseline recordings of ECG in 1 -3 minutes intervals will be done before dosing 
at visit 1(baseline). The HR,RR, PR and QT intervals and QRS duration will be analysed in the 
central ECG laboratory . QTc will be calculated using both Bazet t’s and Fridericia’s correction. 
Each ECG will be assessed as normal/abnormal by [CONTACT_81131] . Clinical 
significance of the abnormalities will be assessed by  [CONTACT_093].
DNO 090017ff823c9bac  /  . 40 / 58 DNO 090017ff823c9bac Approved  /  1.0 40 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
Addi tional 1-2assessments of 12-lead ECG should be performed within 5-10 minutes from each 
other (all before the morning dose ), if the HR in the first recording was increased from baseline 
(visit 1) as follows:
> [ADDRESS_877712] is receiving the study treatment 1 mg b.i.d., to assess the need for 
dose reduction (see section 5.3.2 )
> [ADDRESS_877713] is receiving the study  treatment 1 mg once daily, to assess the 
need for discontinuation (see section 4.5 )
Ifthe HR increa seis not repeated in the second ECG, no further ECG recordings areneeded.
Physical examination will be performed at screening and the end -of-study  visit. Weight will be 
measured at screening, at visits 1, 3, 4, 5, 6, 7, [ADDRESS_877714] questions at screening, at each visit 
during the treatment period before dosing , and at the end-of- study  visit :
Screening:
1.During the past [ADDRESS_877715] you wished you were not alive anymore or had any 
thoughts about ending your life ?
2.During the past [ADDRESS_877716] you done anything or prepared to do anything to end your 
life?
Treatment period and end-of- study : 
1.Since the last visit, have you wished you were not alive anymore or had any thoughts 
about ending your life ?
2.Since the last visit, have you done an ything or prepared to do an ything to end y our life?
The second question (2) will be asked only in cases where the answer to the first question (1) 
has been ‘yes’.
6.5.[ADDRESS_877717] 10 hours of fasting:
Haematology: 
Haemoglobin
Haematocrit
Erythrocy te count
Leukocy te count
Platelet count
Differential count (l ymphocy tes, monocy tes, eosinophils, neutrophils, basophiles)
Mean corpuscular volume
DNO 090017ff823c9bac  /  . 41 / 58 DNO 090017ff823c9bac Approved  /  1.0 41 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
Mean corpuscular haemoglobin
Chemistry:
Albumin
Alkaline phosphatase (ALP)
Bilirubin total
Bilirubin conjugated
Calcium
Creatine kinase
Creatinine
Creatinine clearance
C-reactive protein
Gamma -glutam yl transferase (GGT)
Alanine aminotransferase (ALT)
Aspar tate aminotransferase (AST)
Glucose
Lactate deh ydrogenase
Potassium
Sodium
Troponin T
TSH 
Urinalysis: 
Glucose
Protein
Erythrocy tes
Leucocy tes
Serology: 
Hepatitis B surface antigen (HBsAg)
Hepatitis C virus antibody  (HCVAb)
Haematology , chemistry  (except TSH) and urinaly sis will be repeated at each visit during the 
treatment period and at the end -of-study  visit.
A pregnancy  test for female subjects of childbearing potential will be performed at screening 
and baseline and at each visit during the treatment period (except visit 2, i.e. 2 weeks after 
baseline) and at the end -of-study  visit.
The investigator will review all laboratory  results and assess them for clinical significance. In 
case there are abnormal findings, control assessments can be performed according to the 
judgement of the investigator.
Instructions for the collection , handling, storage and transportation of samples will be provided
before the start of the study .
6.6 Changes implemented due to COVID -19 pandemic
In case visits 7 (Week 36), 8 (Week 48) and/or end-of-study  visit (14-25 days after visit 8) 
described in Table 1and in sections 6.1.2 and 6.1.5 cannot be conducted at the study  centre 
DNO 090017ff823c9bac  /  . 42 / 58 DNO 090017ff823c9bac Approved  /  1.0 42 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
within the visit window due to restrictions related to COVID -19,a telephone visit (could also be 
a home visit or video call) should be arranged. 
The telephone visit should include all protocol assessments that can be performed remotely (see
table below) and should take place within the original visit window. The decision to replace the 
study  centre visit with a telephone contact [CONTACT_654230] b y cas e,and the 
sponsor sho uld be informed of each case as earl y as possible.
In addition to the telephone visit, the investigator should make reasonable efforts to obtain [ADDRESS_877718] at the time of stoppi[INVESTIGATOR_14917]. All safety  
datawhich are possible to obtain locall yshould be collected prior (on treatment) or at the remote 
visit: the study  treatment should be stopped at the time of the remote visit. 
The following assessments will not be performed at telephone visits: SVC supi[INVESTIGATOR_050], weight, sitting 
or orthostatic changes in vital signs, blood sampling for levosimendan, OR -[ADDRESS_877719] on study results, such as 
tests done in a local laboratory , will be explained, assessed and reported in the clinical study  
report following ICH E3.
DNO 090017ff823c9bac  /  . 43 / 58 DNO 090017ff823c9bac Approved  /  1.0 43 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877720]. A copy of the trace (paper or electronic) should be provided.
3Standard biochemical, electrolyte and haematological test panels of the local laboratory will be accepted. A copy 
of the laboratory report w ith local refe rence range should be provided.
4Test kits for urine pregnancy test should be provided to the subject for testing at home (unless taken in a local 
laboratory ).
7.DATA COLLECTION AND M ANAGEMENT
The investigators and study  centre personnel will prepare and ma intain accurate source data for 
each study  subject about clinical findings specified in the protocol. Source data include patient 
records, laboratory  results and questionnaires if not collected electronically . The data from 
source documents will be recorde d into an electronic data capture (EDC) system ,Medidata Rave 
(Medidata Inc), using eCRFs at the study  centre. Safet y laborator y, spi[INVESTIGATOR_654182] y and results will be uploaded to the Rave sy stem and electronically  signed by 
[CONTACT_36705]. All data on the eCRFs must be verifiable in the source data or patient records 
unless eCRF data are declared as source data.
DNO 090017ff823c9bac  /  . 44 / 58 DNO 090017ff823c9bac Approved  /  1.0 44 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877721] data on the eCRFs.
Electronic queries about missing, misleading, incomplete or illogical data will appear in the EDC 
system. An audit trail within the system will track all changes/corrections made. The investigator 
has to confirm the content of the eCRF with an electronic signature.
Individual data fields in the EDC system may be locked on an ongoing basis during the study . 
The fields may  be unlocked if further updates are n eeded. When all data have been entered and 
all queries resolved, the whole database will be locked. Only authorised and well-documented 
updates to the study  data are possible after the database lock. 
Further details regarding data collection and managemen t are presented in the data management 
plan.
8.STA TISTICA L METHODS
8.[ADDRESS_877722] 
matching placebo in SVC (supi[INVESTIGATOR_050]) at12 weeks. The statistical hypothesis will be two-sided 
comparing change from baseline to 12 week pre-dose sample using the mixed model for repeated 
measures (MMRM) at a nominal 5% significance level.
H0: ∆SVC% levosimendan = ∆SVC% placebo
H1: ∆SVC% levosimendan ≠ ∆SVC% placebo
8.2 Estimation of sample size
Sample size estimation is primarily based on the study 3119001 LEVALS SVC (supi[INVESTIGATOR_050]) results 
(Table 6). The LEVALS study  had placebo controlled data only up to [ADDRESS_877723] from phase II tirasemtiv trial 
BENEFIT -ALS (Shefner JM et al., 2016 )is also evaluated.
Assuming at least 3.6% differenc e between treatment arms and common standard deviation of 
10%, [ADDRESS_877724] 90% power to detect a statistically  significant difference at 
two-sided 5% level using 1:[ADDRESS_877725]. Randomisation of 
450subjects to study using a 2:1 allocation ratio (approxi mately  300 levosimendan and 
150placebo treated subjects) allows approximately 20% drop out rate.
Based on dexpramipexole phase III study  EMPOWER (Cudkowicz ME et al., 2013 )12 point 
reduction in total ALSFRS -R score and a15% mortality  rate at [ADDRESS_877726] deviation , in 
ALSFRS -Rand 20% relative improvement in survival 450 patients provide approximately  80% 
simulated power to detect statistically  significant difference using joint rank test. With 450 
subjects and assuming 48 week levosimendan event rate of 73% and hazard ratio of 0.70, time 
to respi[INVESTIGATOR_654183]  70% power to detect statistically  significant difference 
using log -rank test.
DNO 090017ff823c9bac  /  . 45 / 58 DNO 090017ff823c9bac Approved  /  1.0 45 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
Table 6. Mean (SD) change from baseline SVC (supi[INVESTIGATOR_050])
Treatment 2 weeks 12 w eeks
Levosimendan 1 mg x 2 +2.4 (8.3) -4.9
Levosimendan 1 mg x 1 +0.8 (8.6)
Placebo -3.6 (9.4) -17.71
Placebo (BENEFIT -ALS) -1.4 -8.5
1Extrapolated from the data
SD = standard deviation
8.3 Analysis populations
Intent -to-treat (ITT) dataset, including all randomised subjects, will be used for the primary  
evaluation. Sensitivity  analyses using full analy sis set (FAS) and per-protocol (PP) dataset will 
be performed and described in the SAP . FAS includes all treated subjects with at least one post 
baseline SVC measurement .PP dataset includes all randomised subjects exclud ingsubjects with 
relevant major protocol deviations. All subjects who received any study  treatment will be 
included in the evaluation of safet y. Subject classification will be completed during the blind 
review before the database lock and opening the treatment code.
8.[ADDRESS_877727] coding 
dictionaries.
8.4.2 Treatment compliance and extent of exposure
The number of exposed subjects, the number of dispensed and returne d study  treatments and the 
duration of study  treatment exposure will be tabulated with descriptive statistics.
8.4.3 Analysis of efficacy
The primary  efficacy  variable SVC (supi[INVESTIGATOR_050]) will be compared between the treatment arms using 
the MMRM with between subject effects for treatment, centre and randomisation strata, time as 
within subje ct effect, and baseline value (visit 1) as a covariate. Primary  efficacy  will be 
evaluated at12 weeks using contrasts to obtain estimates from the primary model including all 
SVC measurements prior to [ADDRESS_877728] of missing data imputation will be evaluated analysing observed data 
only and estimating the slope of decline using the random slope model .Several sensitivity  
subgroup analyses will be performed and defined in the SAP. Additional evaluations will be 
performed including all data through 48 weeks , using the MMRM.
DNO 090017ff823c9bac  /  . 46 / 58 DNO 090017ff823c9bac Approved  /  1.0 46 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
Secondary  efficacy  endpoints will be tested in following hierarch y to preserve the overall alpha 
level:
1.Combined assessment ofALSFRS -R function and survival th rough 48 weeks
2.Time to respi[INVESTIGATOR_654184] 48 weeks
3.CGI through 48 weeks
4.Supi[INVESTIGATOR_654133] 10 scale at12weeks
5.Slope of decline inrespi[INVESTIGATOR_654185] -Rthrough 48 weeks
The efficacy  variables time to respi[INVESTIGATOR_654124], time to NIV or death, time to SVC (supi[INVESTIGATOR_050]) 
decline of 20%, time to SVC (supi[INVESTIGATOR_050]) ≤ 50% of predicted, time to ALSFRS -R total score decline 
of 20 % and time to decline in AL SFRS -R respi[INVESTIGATOR_654186]’s 
proportional regression model. The m odel will include effect for treatment and will be adjusted 
for randomisation strata. Premature discontinuations will be censored from the analyses.
Censoring rules will be defined in the SAP.
The efficacy  variables A LSFRS-R total score and its subdomain scores will be performed 
through 48 weeks. Primary analysis will combine change from baseline to 48 weeks and survival 
through 48 weeks in joint rank anal ysis (Berry  JD et al., 2013 )using Wilcoxon -Mann -Whitney  
test. Slope of decline will be estimated using the random slope model. Additional analy ses will 
be conducted using the MMRM and estimates for individual time points will be done using 
contrasts. Imputation of missing data using the multiple imputation method will be considered.
CGI, Borg CR10 (sitting , supi[INVESTIGATOR_654136]) , ESS andPSQI will be evaluated using 
the MMRM and estimates for individual time points will be done using contrasts. In addition 
categorical analyses for ESS andPSQI  will be performed using repeated measures logistic 
regression using the generalised estimating equation (GEE) approach .
All efficac y data will belisted andsummarised over the time and by [CONTACT_654231]. Health and home care resource use data will be summarised in 
thestudy  report, but any further analysis for potential pharmacoeconomic purposes will be 
reported separatel y.
8.4.[ADDRESS_877729] 
acetylation status.
8.4.5 Population PK/PD modelling
A population pharmacokinetic/pharmacod ynamic (PK/PD) model between OR-[ADDRESS_877730] relationship with PD
endpoints.
8.4.6 Evaluation of pharmacogenomics
Acet ylation status will be determined from all subjects participating in the study  and the results 
will be source data. Acety lation status will be summarised by  [CONTACT_654232]. The effects of 
DNO 090017ff823c9bac  /  . 47 / 58 DNO 090017ff823c9bac Approved  /  1.0 47 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
acetylation status on OR-1896 and OR-1855 pharmacokinetics and on SVC and HR will be 
evaluated using analy sis of variance (ANOVA ).
In the context of this study , genetic polymorphisms will be analy sed in relation to significant 
variation or speci fic scientific questions in PK, PD or safet y variables of levosimendan. These 
pharmacogenomic anal yses appl y only to those subjects who have signed a separate IC for PG. 
If such analy sis isperformed, the results will be reported in a separate report.
8.4.[ADDRESS_877731] coding 
dictionaries.
[IP_ADDRESS] Analysisof adverse events
AEs reported during the study  will be classified by [CONTACT_654233] (MedDRA) coding system. The AEs will 
be display ed in a frequency  table. The number and proportion (%) of subjects having each AE 
will be given, the severity  of AEs (mild, moderate, severe) and causalit y to the study  treatment 
will be evaluated. SAEs and other significant AEs will be evaluated case by [CONTACT_23353]. AEs occurring 
before and after the start of study  treatment will be reported separatel y.
[IP_ADDRESS] Clini cal safety analysis
Vital signs (supi[INVESTIGATOR_654187], systolic and diastolic BP) as well as standard 12-lead 
ECG variables will be tabulated by [CONTACT_3148]. Potential treatment effects willbe analysed using 
the MMRM. The number of subjects with QTc interval prolongation will be classified and 
summarised. The details of the MMRM model and categorical analyses will be defined in the 
SAP. Abnormal ECG findings , special situations and physical examination findings will be 
summarised by  [CONTACT_558795] g descriptive statistics.
[IP_ADDRESS] Laboratory safety analysis
Safety  laboratory  results will be primarily  evaluated using descriptive statistics and line plots
only. Potential treatment effects may be analy sed using the MMRM, if deemed necessary . The 
frequencies of normal and abnormal safet y laboratory  findings will be summarised based on the 
provided reference ranges of the respective laboratory ,and the clinical significance of the 
findings will be evaluated .
DNO 090017ff823c9bac  /  . 48 / 58 DNO 090017ff823c9bac Approved  /  1.0 48 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
[IP_ADDRESS] Analysis of prior and concomitant treatments
Prior and concomitant treatments will be coded using the anatomical therapeutic chemical 
(ATC) classification system . The number and percentage of subjects using concomitant 
treatments will be summarised b y pharmacological subgroup and chemical substance. 
[IP_ADDRESS] Analysis of suicidality
Suicidality  will be summarised b y treatment group using descriptive statistics.
8.5 Interim analy ses
Interim/futility  analyses will be done when approximately  50% and 100% of the subjects have 
been treated for 12 weeks. Futility  will be evaluated using SVC% response and time to 
respi[INVESTIGATOR_654188]. Based on the estimation ,approximately  35% and 75% of the 
respi[INVESTIGATOR_654189].Stoppi[INVESTIGATOR_654190] O’Brien- Fleming t ype of boundaries (O'Brien PC et al., 1979 , Lan GKK et al., 1983) . Exact 
alpha spending for futility  analyses will be based on the actual amount of information used and 
aredetailed in a DSMB charter . An independent DSMB will perform and evaluate the 
interim/futility  analy ses and make recommendations for the study  conduct .
9.DATA QUA LITY ASSURA NCE
9.1 Training
An investigator s’meeting will be arranged for the investigators and other relevant study  centre 
personnel. This meeting will include a review of the protocol, CRF completion and study  
procedures as well as training on efficacy  assessments like supi[INVESTIGATOR_654191] -R.
The investigators will ensure that appropriate training relevant to the study is given to the 
medical, nursing and other personnel involved in the study . The investigators will also ensure 
that any information relevant to the conduct of the study  is forwarded to other relevant study  
centre personnel.
9.2 Case report forms
Electronic queries about missing, misleading, incomplete or illogical data will appear in the EDC 
system. An audit trail within the system will track all changes/corrections made. The investigator 
has to confirm the content of the eCRF with an electronic signature.
9.3 Monitoring, audits and inspections
The study  monitor will visit the study  centre regularl y as agreed by [CONTACT_31374]. The study  monitor will ensure that the study  complies with good clinical practice (GCP) 
and applicable regulatory requir ements and that the protocol is followed in all aspects, including 
the randomisation procedure, accurate recording of results, reporting of AEs, drug accountability 
and record keepi[INVESTIGATOR_007]. Furthermore, it will be verified that the clinical facilities remain appropriate , 
DNO 090017ff823c9bac  /  . 49 / 58 DNO 090017ff823c9bac Approved  /  1.0 49 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
and that the CRFs correspond with source data. Further details regarding monitoring are 
presented in the monitoring manual.
The study  may be audited by [CONTACT_654234](s) of the sponsor or inspected by [CONTACT_654235] ( CAs).For these purposes, the study monitor, auditors and inspectors will 
be allowed direct access to hospi[INVESTIGATOR_654192]/source data of the study subjects, original 
laboratory  data etc., as far as they  are related to the study .
It is essential that theinvestigator and other relevant members of the study  centre team are 
available during the monitoring visits, audits and inspections, and that they devote sufficient 
time to these processes.
9.4 Laboratories and other vendors
A central laboratory will be used for laboratory  safety measurements, ECG analy sesand 
spi[INVESTIGATOR_038] .
Details regarding laboratory  safety measurements, ECG analyses andspi[INVESTIGATOR_654193] .Quality  certificates are required from all safet y laboratories.
Bioa nalytics will be performed using validated methods.
10.FURTHER REQUIREMENT SAND GENERA L INFORMA TION
10.1 Investigators and study  administrative structure
10.1.1 Investigators
Should the investigator transfer one of his/her responsibilities to other members of the study 
centre team, he/she must have this approved by [CONTACT_654236].
In the event of changes in key study centre team members, the responsible investigator must 
ensure that the successor is fully  informed and capable of following the procedures.
A curriculum vitae in English must be obtained from all investigators who sign the protocol, and 
from other relevant persons.
10.1.[ADDRESS_877732] sof the study subjects and all others who may  possibly  be exposed to 
study  treatments. The DSMB safet y meetings will occur by[CONTACT_654237] . 
The DSMB will also perform and evaluate formal futility /interim analyses and make 
recommendations for the study  conduct. 
Further details regarding the composition and responsibility  of the DSMB are presented in a
DSMB charter.
DNO 090017ff823c9bac  /  . 50 / 58 DNO 090017ff823c9bac Approved  /  1.0 50 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877733] be approved by [CONTACT_456], and when required by [CONTACT_1383]/IRBor CA. Only  in the event 
of a need to eliminate an immediate hazard(s) to study subjects, the in vestigator may implement 
a deviation from the protocol without prior approval.
Any change or addition to the approved study  protocol may lead to suspension of the study  or 
its results.
Any changes to the study protocol are subject to prior discussion with, and approval by, the 
sponsor and the study  coordinating investigator. As a general rule, protocol amendments should 
be approved according to the same procedures as the study  protocol.
Amendments are regarded as substantial, where they are likely to have asignificant impact on 
the safet y, ph ysical or mental integrit y of the study subjects, or the scientific value of the study. 
An approval of the responsible EC /IRBor CA shall be obtained before substantial amendments 
may be implemented, unless local regula tions are different.
If an amendment contains only minor changes (typi[INVESTIGATOR_654194]) not affecting the safet y, 
physical or mental integrity  of the study  subjects, or the scientific value of the study , the EC/IRB
or CA need not to be notified and in-house approval (including approval by [CONTACT_654238]) is adequate.
10.3 Insurance
The sponsor will provide clinical trial liability  insurance for study  subjects in all participating 
countries according to local regulations.
10.4 Financial disclosure
The investigator will be required to disclose an y financial arrangement whereb y the value of the 
compensation for conducting the study  could be influenced by [CONTACT_58435] ; any 
significant pay ments of other sorts from the sponsor, suc h as a grant to fund on -going research, 
compensation in the form of equipment, retainer for on-going consultation, or honoraria; any 
proprietary  interest in oral levosimendan ; any significant equity  interest in the sponsor as defined 
in the US Code of Fede ral Regulations [21 CFR 54 2(b)].
In consideration of participation in the study , the sponsor will pay the investigator, or nominated 
payee the sums set out in the pay ment schedule attached to the Investigator Agreement.
10.[ADDRESS_877734]’s last visit or last contact [CONTACT_476688].
Study  centres will be closed upon study  completion. A study  centre is considered closed when 
all required documents and study  supplies have been collected and a study 
completion/ termination visit has been performed .
DNO 090017ff823c9bac  /  . 51 / 58 DNO 090017ff823c9bac Approved  /  1.0 51 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877735] all participating study  subjects within 7 days,and invite them for 
anend-of-study  visit .
10.6 Reports, publications and communication of results
Orion wishes to collaborate with the investigator sto publish the results as timely  as possible, 
without compromising accuracy  or industrial property  rights.The preparation, submission and 
authorship for publications containing the study  results shall be in accordance with a process 
determined by [CONTACT_654239] t among the sponsor and participating 
investigators/institutions, and in accordance with international criteria for authorship; see 
International Committee of Medical Journal Editors recommendations, available at 
http://www.icmje.org .
Orion remains the exclusive owner of the study  data defined by  [CONTACT_760].
This study  will be registered in one of the acceptable registries before the enrolment of the first 
subject .
10.7 Retention of records
The investigator agrees to keep the following documentation in the investigator’s study  file: 
study  subject records, including a subject screening log, a subject identification list, all original 
signed IC forms, a cop y of CRFs and records of drug dispensing. 
The study  files at the study centres will be stored in the respective archives for [ADDRESS_877736] information sheet, ICform, and all other necessary  documents will 
be submitted to an independent EC/IRBfor review according to local regulations.
The investigator is responsible for obtaining a favourable opi[INVESTIGATOR_349894]/IRBfor the study , 
submitting any amendment(s) ,and communicating study -related safet y issues as requested by 
[CONTACT_1383]/IRB. The investigator should file all correspondence with the EC/IRB in the 
investigator’s study  file. Relevant copi[INVESTIGATOR_654195].
11.[ADDRESS_877737] of the study
The study  will be conducted in accordance with the Declaration of Helsinki guiding phy sicians 
in biomedical research involving human subjects.
DNO 090017ff823c9bac  /  . 52 / 58 DNO 090017ff823c9bac Approved  /  1.0 52 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
The study  shall not be initiated before favourable opi[INVESTIGATOR_349894]/IRBand approval from 
the CA has been obtained for the protocol, including its appendices.
The study  will be conducted in compliance with the protocol, GCP (ICH/135/95) and applicable 
regulatory  requirements. A substantial amendment shall not be implemented until the protocol 
amendment has received favourable opi[INVESTIGATOR_654196]. Only  in 
case of the need to eliminate an immediate hazard(s) to study  subjects, the investigator may 
implement deviation from the protocol without prior favourable opi[INVESTIGATOR_654197].
In case of serious breaches, the Medicines and Healthcare Products Regulatory  Agency  (MHRA )
GCP I nspectorate must be notified according to MHRA Guidance for the notification of serious 
breaches of GCP or the study  protocol (see http://www.mhra.gov.uk ).
11.[ADDRESS_877738]’s CRF and also on the subject screening lo g and identification list.
11.[ADDRESS_877739] number, birth yearand 
sex.
The c onfidentialit y of PGdata will be pr otected according to local laws and regulations.
DNO 090017ff823c9bac  /  . 53 / 58 DNO 090017ff823c9bac Approved  /  1.0 53 / 58

ODM -109
Clinical study protocol 3119002 – Amendment [ADDRESS_877740]
Andersen PM et al. (2012) EFNS guidelines on the clinical management of am yotrophic lateral 
sclerosis (MALS) --revised report of an EFNS task force. Eur J Neurol. 19 (3): 360-75.
Baumann F et al. (2010) Use of respi[INVESTIGATOR_654198]. Amyotrophic lateral sclerosis : official publication of the World 
Federation of Neurology  Research Group on Motor Neuron Diseases. 11 (1 -2): 194-202.
Bensimon G et al. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. 
ALS/Rilu zole Study  Group. N Engl J Med. 330 (9): 585 -91.
Berry  JD et al. (2013) The Combined Assessment of Function and Survival (CAFS): a new 
endpoint for ALS clinical trials. Amy otroph Lateral Scler Frontotemporal Degener. 14 
(3): 162-8.
Borg GA (1982) Psychophy sical bases of perceived exertion. Medicine and science in sports 
and exercise. 14 (5): 377 -81.
Brooks BR et al. (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic 
lateral sclerosis. Amy otroph L ateral Scler Other Motor Neuron D isord. 1 (5): 293-9.
Buysse DJ et al. (1989) The Pi[INVESTIGATOR_10797]: a new instrument for psychiatric 
practice and research. Psychiatry research. 28 (2): 193 -213.
Cedarbaum JM et al. (1999) The ALSFRS -R: a revised ALS functional rating scale that 
incorporates assessments of respi[INVESTIGATOR_4806]. BDNF ALS Stud y Group (Phase III). J 
Neurol Sci. 169 (1- 2): 13 -21.
Cudkowicz ME et al. (2013) Dexpramipexole versus placebo for patients with amyotrophic 
lateral sclerosis (EMPOWER): a randomised, double -blind, phase 3 trial. Lancet Neurol. 
12 (11): 1059 -67.
Deschodt -Arsac V et al. (2010) Absence of mitochondrial activation during levosimendan 
inotropic action in perfused paced guinea pig hearts as demonstrated by [CONTACT_654240]. Am J Physiol Regul Integr Comp Physiol. 299 (Copy right (C) 2015 U.S. 
National L ibrary  of Medicine.): R786-92.
Doorduin J et al. (2012) The calcium sensitizer levosimendan improves human diaphragm 
function. Am J Respir Crit Care Med. 185 (1): 90 -5.
Haikala H et al. (1995) Troponin C -mediated calcium sensitization by  [CONTACT_654241]. J Mol Cell Cardiol. 27 (10): 2155 -65.
Hewitt CE et al. (2006) Is restricted randomisation necessary ? BMJ (Clinical research ed). 332 
(7556): 1506-8.
Johns MW (1991) A new method for measuring daytime sleepi[INVESTIGATOR_008]: the Epworth sleepi[INVESTIGATOR_217073]. Sleep. 14 (6): 540 -5.
Kivikko M et al. (2015) Oral Levosimendan Increases Cerebral Blood Flow Velocities in 
Patients with a History  of Stroke or Transient Ischemic Attack: A Pi[INVESTIGATOR_654199]. 
Current therapeutic research, clinical and experimental. 77: 46-51.
Lan GKK et al. (1983) Discrete sequential boundaries for clinical trials. Biometrika. 70 (3): 659-
663.
DNO 090017ff823c9bac  /  . 54 / 58 DNO 090017ff823c9bac Approved  /  1.0 54 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
Lechtzin N et al. (2002) Spi[INVESTIGATOR_654200]. Chest. 121 (2): 
436-42.
NICE guideline [NG42]. Motor neurone disease: assessment and management. Last updated 
February  2016. https://www.nice.org.uk/guidance/NG42
Nieminen MS et al. (2008) Oral levosimendan in patients with severe chronic heart failure --the 
PERSI ST study . Eur J Heart Fail. 10 (12): 1246 -54.
O'Brien PC et al. (1979) A m ultiple testing procedure for clinical trials. Biometrics. 35 (3): 549 -
56.
Press release (2017) http://markets.businessinsider.com/news/stocks/Cy tokinetics -Announces -
Presentation -of-Results- From -VITALITY -ALS -at-28th-International -Symposium -on-
ALS-MND -[PHONE_13557] , Markets Insider.
Schmidt EP et al. (2006) Pulmonary  predictors of s urvival in amy otrophic lateral sclerosis: use 
in clinical trial design. Muscle & nerve. 33 (1): 127-32.
Shefner JM et al. (2016) A randomized, placebo -controlled, double -blind phase IIb trial 
evaluating the safet y and efficacy  of tirasemtiv in patients with amyotrophic lateral 
sclerosis. Amy otroph Lateral Scler Frontotemporal Degener. 17 (5 -6): 426 -35.
Turner MR et al. (2013) Controversies and priorities in amyotrophic lateral sclerosis. Lancet 
Neurol. 12 (3): 310-22.
van Hees HW et al. (2011) Levosimendan improves calcium sensitivity  of diaphragm muscle 
fibres from a rat model of heart failure. Br J Pharmacol. 162 (3): 566 -73.
van Hees HW et al. (2009) Levosimendan enhances force generation of diaphragm muscle from 
patients with chronic obstructive pulmonar y disease. Am J Respir Crit Care Med. 179 
(1): 41-7.
Zinman L et al. (2011) Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet 
Neurol. 10 (5): 481-90.
DNO 090017ff823c9bac  /  . 55 / 58 DNO 090017ff823c9bac Approved  /  1.0 55 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
13.SUMMA RY OF CHA NGES TO AMENDMENT 2
13.1 Revision history
Protocol and amended protocols Date Applies to
Clinical study protocol 20October 2017 Global
Amendment 1 -Amended clinical study protocol 05January 2018 Global
Amendment 2 -Amended clinical study protocol 17April 2018 Global
Amendment 3 -Amended clinical study protocol 26March 2020 Global
Country specific amendments Date Applies to
Amendment 1 27 Mar 2018 Sweden
Amendment 1 06Apr 2018 The [LOCATION_008]
Amendment 1 16 Apr 2018 Belgium
13.2 Summary  of changes
The changes incorporated in this amended protocol from the Amendment 2 –Amended clinical study  protocol dated 17April 2018
are described in the following. Themodifications of the text are indicated by [CONTACT_246038] (for deletions) andunderline (for additions).
DNO 090017ff823c9bac  /  . 56 / 58 DNO 090017ff823c9bac Approved  /  1.0 56 / 58

ODM -109
Clinical study protocol 3119002 – Amendment 3
The following changes were made due to COVID -19 pandemic :
Section Previous text New text Rationale for the change
6.6 Changes 
implemented due 
to COVID -19 
pandemic- Whole text is new, see the section 6.6. New section describing 
changes due to COVID -19 
pandemic added
In addition,
the table of contents was updated to reflect the headings and pagination of the current document .
thetitle page and header and footer sections were updated to reflect the version details of the current document .
the approver information wasupdated.
DNO 090017ff823c9bac  /  . 57 / 58 DNO 090017ff823c9bac Approved  /  1.0 57 / 58

ODM -109
Clinical study protocol 3119002 –Amendment 3
14.APPENDICES
Appendix 1 .Investigator signature
[CONTACT_654242] 090017ff823c9bac  /  . 58 / 58 DNO 090017ff823c9bac Approved  /  1.0 58 / 58
